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Résumé 
Panni les signes qui font partie de la définition clinique de la schizophrénie, figurent 
les symptômes négatifs. Ces symptômes négatifs (le retrait social, l'émoussement des 
affects, l'avolition, etc.) sont des signes qui sont difficiles à traiter. Différentes stratégies 
médicamenteuses ont été proposées. Dans ce mémoire de maîtrise, nous avons examiné une 
des modalités de potentialisation de l'effet habituel des médicaments antipsychotiques sur 
les symptômes de la schizophrénie pour traiter ces symptômes négatifs. Les médicaments 
que nous avons étudiés en tant que potentialisateurs sont les inhibiteurs sélectifs de la 
recapture de la sérotonine (ISRS) qui sont habituellement prescrits pour traiter les épisodes 
dépressifs majeurs mais qui ont également été essayé dans le traitement des symptômes 
négatifs de la schizophrénie. Les résultats d'essais contrôlés de cette potentialisation ont fait 
l'objet de plusieurs publications et nous avons voulu, dans le cadre de cette maîtrise, faire 
l'examen de l'effet de la potentialisation des médicaments antipsychotiques par les ISRS 
pour traiter les symptômes négatifs en utilisant une approche de revue de littérature 
quantitative que l'on désigne de méta analyse. Dans ce mémoire, nous avons rédigé une 
mise àjour de la méthodologie propre aux méta-analyses conformément aux critères établis 
par le groupe Cochrane. Nous avons pu ainsi définir quelles étaient les étapes nécessaires à 
diriger une méta-analyse avec un ensemble de données continues. Nous avons détaillé 
l'ensemble de ces étapes et appliqué par la suite l'approche méta analytique à l'hypothèse 
suivante: est-ce que les ISRS, lorsqu'ils sont utilisés pour potentialiser les médicaments 
antipsychotiques pour traiter les symptômes négatifs dans la schizophrénie sont efficaces. 
IV 
En recueillant les études de la façon la plus exhaustive possible et en réunissant le 
nombre de patients impliqués dans ses études, sélectionnés en fonction de critères 
d'exclusion et d'inclusion, nous avons abouti aux résultats suivants: 
Onze études ont répondu à nos critères d'inclusion. Avec le modèle d'effet aléatoire, 
le taille de l'effet obtenue mesurant les changements de l'intensité des symptômes négatifs 
était non-significative (N= 393; Hedges' 0.178; p= 0.191). Cependant, quand des études 
ont été divisées selon la sévérité de la maladie, une taille de l'effet modérée a émergé 
significativement pour les études faisant participer des patients désigné • chroniques' (N= 
274; Hedges' g= 0.386; p= 0.014). 
En conclusion, la méta-analyse que nous avons réalisée et publiée montre un effet 
négligeable de l'addition des ISRS au traitement antipsychotique habituel pour traiter les 
symptômes négatifs de la schizophrénie. Dans la discussion nous analysons les limites et 
les conséquences de ces résultats. 
Mots-clés: Schizophrénie, poly-thérapie, méta-analyses, antipsychotique, inhibiteurs 
sélectifs de la recapture de la sérotonine, ISRS. 
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Résumé (English) 
The negative symptoms of schizophrenia (social withdrawal, fiat affect, avolition, 
etc.) are difficult to treat. Various medication strategies have been proposed. In this 
manuscript, we examine one of the methods of potentiation of antipsychotic drugs for the 
treatment of the negative symptoms in schizophrenia. The drugs which were studied as 
potentiation agents are the mono amine selective serotonin reuptake inhibitors (SSRIs) 
which are primarily prescribed to treat major depressive episodes, but are also prescribed in 
the treatment of the negative symptoms of schizophrenia. Several controlled clinical trials 
examining the effects of SSRIs in schizophrenia were published. This manuscript, 
examines the effect of potentiation of the antipsychotic agents, via SSRIs for the treatment 
of negative symptoms using a quantitative systematic review of the literature. 
The meta-analytic method used is in accordance with the criteria established by 
Cochrane. Additionally, stages necessary to direct meta-analysis with continuous data were 
brought into prominence. Consequently, we have applied the meta-analytic approach to the 
following assumption: SSRIs are effective when they are used as a potentiation agent to 
antipsychotic drugs to treat the negative symptoms in schizophrenia. 
Subsequently, by investigating exhaustively the available studies and us mg 
inclusion (a- SSRI add-on therapy was compared with antipsychotic monotherapy among 
schizophrenia spectrum disorder patients; b- the clinical trials were randomized, double 
blind, placebo-controlled with parallel-arm design; c- negative symptoms were assessed 
with the Sacle for the Assessment of the Negative Symptom or Positive and Negative 
VI 
Syndrome Scale-negative subscale) and exclusion criteria (1- schizophrenia with 
comorbidity; 2- incomplete or unavailable data; 3- comparison with other compounds such 
as MAOI; 4- cross-over studies), we could, by aggregating the number of patients involved 
in the selected studies, realize a meta-analysis: 
Eleven (n=ll) studies reached inclusion criteria. Within a random-effect model, a 
non-significant composite effect size estimate (end-point) for negative symptoms was 
obtained (N= 393; adjusted Hedges's g= 0.178; p= 0.191). However, when studies were 
divided according to severity of illness, a moderate and significant composite effect size 
emerged for the studies involving the so-called "chronic patients" (N= 274; adjusted 
Hedges's g= 0.386; p= 0.014). 
In conclusion, with the attached published meta-analysis, we have demonstrated an 
insignificant effect for add-on therapy with SSRI's with antipsychotic medication for 
treatment of negative symptoms in schizophrenia. Hence, in the discussion, we have 
analyzed the limitation and consequences of our results. 
Keywords: Schizophrenia, Polytherapy, Meta-analysis, Antipsychotic, Selective serotonin 
reuptake inhibitors, SSRI. 
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Introduction 
2 
In order to increase the efficacy of antipsychotic medication in treatment of 
schizophrenia in both clinical and research settings, polytherapy [more precisely poly-
pharmacy or add-on therapy] is a common avenue for treatment. A recent German study by 
Messer and colleagues underlined the fact that 40 - 50 % of schizophrenia inpatients and 
close to 90 % of schizophrenia outpatients were treated with antipsychotic combination 
therapies (Messer, Tiltscher and Schmauss 2006). Our interest lays in add-on polypharmacy 
with selective serotonin reuptake inhibitors (SSRI), for controlling negative symptoms. 
Literature argues that this approach in treatment is limited and thus making evidence-based 
treatment decision difficult (Buckley and Stahl 2007). In general, very few weIl designed 
published studies address the limitations of SSRI polypharmacy in schizophrenia. To that 
end, most studies are case reports, clinical trials with poor methodology (e.g., pilot studies, 
cross-over designs, or open trials), often with small sample sizes that are not generalizable. 
The inconclusiveness of the results makes evidence-based decision making difficult. Thus, 
conducting a meta-analysis is warranted. 
Using a meta-analytical approach, by converting results of randomized controlled 
trials (ReT) to common metrics (effect size: ES) that would facilitate 'generalizability'; 
hence provide information for future studies. As Peto (Peto 1987) explains, generation of a 
global output based on moderating variables would help in improving clinical decision 
making. 
3 
Using meta-analysis to investigate moderating variables, we atm to assess the 
quality of research methods and clinical approaches III those studies, and possibly 
ascertaining other factors leading to result discrepancies. 
In this vein, a synopsis of the literature on SSRI add-on therapy used for control of 
negative symptoms will be presented with reference to our article. To begin, the reasons for 
using SSRI add-on therapy will be discussed. Next, assessment strategies (scales) of the 
negative symptoms of schizophrenia will be explained. Finally, we will elaborate on the 
rational behind using meta-analysis to answer the above mentioned clinical-research 
queries. In addition, we will briefly review meta-analytic techniques (Bent, Shojania and 
Saint 2004) and answering a series of intricate questions (Maier 2006), related to 
antipsychotic add-on therapy. 
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Symptômes négatifs de la schizophrénie 
5 
Since Bleuler, negative symptoms (apathy, reduced volition and motivation, 
anergia, alogia, blunted affect and social withdrawal) in schizophrenia have been 
considered to be the core features of the disease (Bleuler 1950). According to Kirkpatrick 
and colleagues (Kirkpatrick, Fenton, Carpenter and Marder 2006), primary negative 
symptoms represent about 20-25% of patients suffering from schizophrenia. Particularly 
difficult to treat, these symptoms represent significant obstacles in achieving better global 
functioning (Bottlender, Wegner, Wittmann, Strauss and Moller 1999; Moller, Bottlender, 
Gross, Hoff, Wittmann, Wegner and Strauss 2002), quality of life, social and occupational 
functioning (Buchanan and Gold 1996). 
Several studies demonstrated a correlation between negative symptoms and 
neurocognitive performance in schizophrenia (Liddle 1987; Liddle, Barnes, Speller and 
Kibel 1993; Cuesta and Peralta 1995; Baxter and Liddle 1998). Neuropsychological 
performance in several domains (e.g., memory, executive function, attention) has been 
reported to be a cardinal deficiency in schizophrenia (Green 1998), associated with poor 
functional outcome (Green 1996; Green, Kern, Braff and Mintz 2000), and work 
performance (McGurk and Meltzer 2000). For example, Stip reports a positive correlation 
between temporal organizations (executive task) and negative symptoms (Stip 2006), whilst 
Stirling and colleagues, report on significant association of memory impairment to negative 
symptoms (Stirling, Hellewell and Hewitt 1997). This neurocognitive association with 
negative symptoms complicates treatment. Moreover, negative symptoms seem to emerge 
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from a distinctive pathophysiological pattern associated with etiological risk factors (e.g., 
genetics) (Kendler, Gruenberg and Tsuang 1986). 
First-generation antipsychotic drugs [also called typical or conventional 
neuroleptics] provide only minimal relief of negative symptoms (Meltzer, Sommers and 
Luchins 1986). Second-generation antipsychotic drugs [sometimes called atypical] have 
been developed in an attempt to decrease side-effects of typical neuroleptics, and to 
improve negative symptoms and cognitive performance. That having been said, negative 
symptoms remain mostly refractory to treatment (Moller 2004). This can be explained by 
the heterogeneity of subcategories of negative symptoms in response to treatment regimens. 
Meta-analytical studies have reported the potential benefits of second-generation 
antipsychotics in the treatment of negative symptoms. Nevertheless, these benefits appeared 
to be modest (Leucht, Pitschel-Walz, Abraham and Kissling 1999; Geddes, Freemantle, 
Harrison and Bebbington 2000). 
The role of antidepressant drugs as an adjunctive treatment of negative symptoms 
has been discussed by Siris and later by Silver (Siris, van Kammen and Docherty 1978; 
Silver 2003). In clinical practice, it has been estimated that antidepressants are prescribed 
as adjunctive treatment in approximately one-third of patients (Addington, Azorin, Falloon, 
Gerlach, Hirsch and Siris 2002). However, add-on therapy with antidepressants such as 
monoamine oxidase inhibitors (MAOI) (Brenner and Shopsin 1980) or tricyclics (TCA) 
(Evins 1996) in schizophrenia have shown to have limited efficacy (Siris, Bermanzohn, 
7 
Gonzalez, Mason, White and Shuwall 1991). More recently, SSRIs have been investigated 
as "augmentation therapy" for the negative symptoms in schizophrenia. 
Hence, we have conducted a meta-analysis by aggregating data from the existing 
literature, in order to determine the effect of SSRI add-on therapy for the negative 
symptoms. 
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Évaluation des symptômes négatifs 
9 
There are several scales available for research and clinical purposes in order to 
identify and measure changes in the negative symptoms of schizophrenia (Andreas en and 
Olsen 1982) or deficit form schizophrenia (Carpenter, Heinrichs and Wagman 1988) or 
type II schizophrenia (Crow 1985). Sorne of the se scales help in diagnosis of patients with 
"deficit syndromes", or rate the severity of the negative symptoms. Others such as scale for 
the assessment of negative symptoms (SANS) were developed to facilitate the 
measurement of changes in negative symptoms. These scales can be categorized as self-
rating scales such as subjective experience deficits in schizophrenia scale developed by 
Liddle and Bames (Liddle and Bames 1988); and include subjective deficit syndrome scale 
whereas others are observer-based rating scale (e.g., SANS). 
Each negative symptom scale usually reflects a particular theoretical approach to 
negative symptoms. For our meta-analysis, we have selected the SANS, first developed in 
1982 by Nancy Andreasen (Andreas en 1982). The original version of SANS provides both 
subjective (Andreas en 1982) (5 items) and raters evaluation of negative symptoms (25 
items). Although, to date, there are no clear guidelines for the evaluation of negative 
symptoms using SANS, it remains the most frequently used scale for the assessment of 
negative symptoms in pharmacological research. Several negative symptom constructs are 
ascertained, with multiple items related to each. The inclusion of more than 1 item 
improves the psychometrics properties of the scale. It is noteworthy that the SANS has 
more items (30 items, original version) than most other rating scales (such as BPRS with 3 
items, or PANSS with 7 times), and moderate to high inter-rater reliability in patient 
10 
assessment (Lecrubier and Boyer 1987; Lecrubier 1997; Silk and Tandon 1991) as well as 
short-term pharmaceutical trials (Lindenmayer 2001). 
11 
Polypharnlacie avec les ISRS 
12 
Perspective clinique 
It is c1ear that the treatmentlcontrol of negative symptoms of schizophrenia remains 
a substantial challenge for the c1inician (Lublin, Eberhard and Levander 2005) (Erhart, 
Marder and Carpenter 2006). In this context, a variety of treatment approaches as 
monotherapy with pharmacological agents, as traditional antipsychotics and later followed 
by atypical antipsychotics have been carried out. Traditional antipsychotics such as 
haloperidol (high-potency) and chlorpromazine (low-potency) are initially prescribed in 
order to control the psychotic, positive (those added to the normal personality) and negative 
symptoms (those that deduct [rom normal personality) of schizophrenia, yet they have 
undesired side-effects (e.g., extrapyramidal symptoms, EPS), and sorne patients continue to 
have persisting schizophrenia symptoms. Additionally, their strong dopamine D2 receptor 
blockade causes or induces negative symptoms similar to the deficit symptoms of 
schizophrenia (Schooler 1994). Knowing this, novel antipsychotics, characterized by 
selective action on neurotransmitters were introduced (e.g., serotoninergic, dopaminergic). 
This was based on lower dopamine D2 receptors occupancy and a better potency as 
serotonin (5-HT) type 2a antagonists, in combination to improve efficacy and tolerability 
for the control of schizophrenia symptoms (Haro, Edgell, Novick, et al, 2005). Yet, in 
select patients, negative symptoms, persist or remain stable over time during treatment 
(Arndt, Andreasen, Flaum, Miller and Nopoulos 1995; Silver 2003). Although patients 
treated with atypical antipsychotics were more responsive than patients treated with 
traditional neuroleptics, sorne patients manifested persisting negative symptoms. However, 
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Moller and colleague' retrospective study using path analysis provided evidence of a direct 
effect of second generation antipsychotics on persisting negative symptoms (Mo lIer, 
Muller, Borison, and Chouinard, 1995). Yet, they carne with limitations, for instance, these 
studies were carried-out with patients suffering from both positive and negative symptoms 
(Lecrubier, Quintin, Bouhassira, Perrin, and Lancrenon 2006). Consequently, clinical 
researchers argued as to whether negative symptoms were due to the same underlying 
pathophysiology as positive symptoms, or simply a side effect of pharrnacological agents 
(Carpenter, Heinrichs and Wagman 1988; Bames and McPhillips 1995). Kirkpatrick et al 
and others proposed specific criteria for diagnosing negative symptoms (Carpenter, 
Heinrichs et al. 1988; Kirkpatrick, Buchanan, McKenney, Alphs and Carpenter 1989). They 
noted that at least 2 of the 6 primary enduring negative symptoms [restricted affect, 
diminished emotional range, poverty of speech, curbing of interests, diminished sense of 
purpose, and diminished social drive] must be present or the persistence of a combination 
of two or more symptoms in the past 12 months. Furtherrnore, the patients have to meet the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for schizophrenia. 
And lastly, these symptoms are not secondary to co-morbid disorders such as anxiety, EPS, 
positive symptoms, mental retardation, and depression. Thus, these concise criteria 
separated primary from secondary negative symptoms. Supporting the necessity of such 
separation was Siris, who suggested that clinical trials should implement appropriate 
measures to control for confounding variables such as depression (Siris 1991). Since the 
neurobiological basis of negative symptoms remain unclear (Tandon and Greden 1989), 
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phase III clinical trials comparing atypical to typical antipsychotic agents were initiated. 
Few attempts at comparing traditional antipsychotics to atypical antipsychotic (selective D2 
blockers) such as Remoxipride were made (Lecrubier, Quintin, Bouhassira, Perrin, 
Lancrenon 2006). Although the effect of Remoxipride was similar to haloperidol on 
positive symptom and persisting negative symptoms, it showed fewer side-effects (Ahlfors, 
Rimon, Appelberg, Hagert, Harma, Katila, Mahlanen, Mehtonen, Naukkarinen, Outakoski 
and et al. 1990; Lewander, Westerbergh and Morrison 1990; Kane 1993). Nonetheless 
other authors reported contradictory results (Chouinard 1990). For example, Lapierre and 
colleagues showed that clinical trials supporting the idea that Remoxipride is beneficial in 
treating persisting negative symptoms was not sufficient to establish its efficacy (Lapierre, 
Ancill, Awad, Bakish, Beaudry, Bloom, Chandrasena, Das, Durand, Elliott and et al. 1992). 
Other studies showed positive results of the atypical, when targeting primary negative 
symptoms (Lapierre, Angus, Awad, Saxena, Jones, Williamson, Vincent, Carle, Lavallee, 
Manchanda, Gauthier, Wolf, Teehan, Denis, Malla, Oyewumi, Busse, Labelle, Claesson 
and Grafford 1999). The later studies had several limitations, for example, they were 
conducted with small sample size that could not provide robust conclusions as to whether 
or not the se agents are efficient for treatment of persisting negative symptoms. To date 
antipsychotics alone have not credibly resolved the problem of persisting negative 
symptoms (Leucht, Pitschel-Walz et al. 1999; Carpenter 2004), consequently encouraging 
the use of alternative therapeutic methods. That having being said, the Food and Drug 
Administration (FDA) endorsement for an indication of negative symptoms and available 
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data, indicate that second generation antipsychotics have not yet met early hopes for a 
highly effective management compound for easing of negative symptoms (Laughren and 
Levin 2006). Moller found that non-responsive patients constituted a subgroup that was 
often responsive to dual treatment (Moller 2004). 
Polypharmacy with SSRI for treatment of negative symptoms in schizophrenia was 
introduced. The clinical underlying principle for the use of antidepressant add-on therapy is 
based on the primary / secondary dichotomy. Negative symptoms are c1assified as primary 
or secondary (Carpenter, Heinrichs et al. 1988; Kirkpatrick, Buchanan et al. 1989). In 
contrast with primary negative symptoms, which are directly related to the schizophrenia 
pathophysiology, secondary negative symptoms result from other psychiatric symptoms 
(e.g. positive symptoms), medication side-effects (e.g. extrapyramidal symptoms) or 
medical conditions (e.g. mental retardation) (Carpenter, Heinrichs et al. 1988; Kirkpatrick, 
Buchanan et al. 1989). In particular, negative symptoms may be secondary to depressive 
symptoms, which share common key symptoms such as anhedonia-asociality and 
avoilition-apathy (Kitamura and Suga 1991; Sax, Strakowski, Keck, Upadhyaya, West and 
McElroy 1996). In this context, the use of antidepressants has been thought to be of 
potential interest in schizophrenia, as the treatment of depressive symptoms would 
eventually lead to a relief of secondary negative symptoms. 
Based on preliminary results, Silver has proposed the usage of SSRI augmentation 
therapy for these enduring symptoms (Silver 2003). However, other studies published so 
far have produced conflicting results (Spina, De Domenico, Ruello, Longobardo, Gitto, 
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Ancione, Di Rosa and Caputi 1994; Lee, Kim, Lee and Suh 1998). A Cochrane registered 
systematic review by Whitehead and associates (Whitehead, Moss, Cardno and Lewis 
2002) showed that add-on antidepressant therapy for schizophrenic patients with co-morbid 
depression may be of therapeutic value; yet, the presence of limitations such as a small 
number of trials, and possible publication bias required that their results be interpreted with 
care. A new quantitative review of seven trials (n=202) by Rummel and colleagues, showed 
that the combination of antipsychotic with antidepressant regimen may perhaps be effective 
in controlling predominant negative symptoms. However, the y included 3 studies only with 
SSRls, and so to draw a conclusion on the efficacy of SSRI add-on therapy would be 
premature. Furthermore, the authors assert that their findings require substantiation by 
further larger-sized trials (Rummel, Kissling and Leucht 2005). 
Most of the previously mentioned studies inc1ude smalI sample sizes ranging from 
20 to 75 patients (Silver and Nassar 1992; Buchanan, Kirkpatrick, Bryant, BalI and Breier 
1996). To detect clinical improvement in psychiatric symptoms measured by positive and 
negative syndrome scale (P ANSS) or brief psychiatric rating scale (BPRS), a 20% 
difference between groups is required, i.e. 150 participants per study arm (a= 0.05; power 
85%)(Thomley and Adams 1998). To reach statistical power, we conducted a meta-analysis 
of studies assessing SSRl add-on therapy for the negative symptoms of schizophrenia. The 
results of this meta-analysis are of therapeutic importance, considering the chronic nature 
of negative symptoms; which may also shed light on the potential role of serotonin in the 
pathophysiology of negative symptoms. 
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Perspective neurobiologique 
There is evidence for a cascade of events leading to the mechanism of action of 
SSRI add-on therapy for the negative symptoms. Negative symptoms are associated with 
ab normal structural changes in the brain (Miller and Tandon 2001). These changes may 
lead to alteration in the circuits involved in shifting motivation (Seeman 2001), inducing 
desensitization (reward system) (Bressan, R. A., Erlandsson, Jones, Mulligan, Flanagan, 
Ell, and Pilowsky 2003; Pycock, Kerwin, and Carter 1980), and ever-increasing 
degeneration (neuroplasticity) (Castner, Williams, and Goldman-Rakic 2000). 
Consequently, these lead to the imbalances of the neurotransmitters (chiefly dopamine and 
serotonin) and hormones (cortisol and pyridostigmine) (O'Keane, Abel, and Murray 1994; 
Saffer, Metcalfe, and Coppen 1985). Hence, by giving antipsychotics to these patients, 
clinicians hope to restore the balance, in the neurotransmitters and the hormones in the 
brain. 
Persisting primary negative symptoms may reqU1re a second medication, 
antidepressant (SSRI) (Silver 2004). However, the mechanism by which the SSRI 
augmentation therapy affects the course of negative symptoms is still unknown; several 
neurobiological hypotheses are postulated below. 
One of the main hypotheses lies in that antipsychotic combined with SSRIs may 
increase levels of dopamine and or neurepinephrine in the prefrontal cortex, resulting in an 
improved antidepressant response (Kapur and Seeman 2001). Specifically, this efficacy is 
18 
driven from enhancing the postsynaptic 5-HT1a mediated neurotransmission. 
Consequently, ln order to comprehend the treatment approach to persisting negative 
symptoms, mechanism of action pertaining to antipsychotic and SSRI, the nature of the 
negative symptoms, and the underlying brain structures and circuit has to be understood. 
Mécanisme d'action des antipsychotiques 
When considering treatment models for schizophrenia, the role of dopamine 
receptor blockade and modulation remains dominant (Seeman and Kapur 2000). The 
optimal binding of dopamine D2 receptors is crucial to balancing efficacy and adverse 
effects. In other words, transient D2 receptor antagonism is sufficient to obtain an 
antipsychotic effect, while permanent D2 receptor antagonism increases the risk of adverse 
effects such as EPS (Stahl 2001a, 2001 b). Partial D2 receptor agonists offer the possibility 
of maintaining optimal b10ckade and function of D2 receptors (Seeman and Kapur 1997). 
Balancing pre-synaptic and postsynaptic D2 receptor antagonism is another probable 
mechanism that can, through increased release of endogenous dopamine in the striatum, 
protect against excessive blockade of D2 receptors (Seeman, Wilson, Gmeier and Kapur 
2006). 
Antipsychotic effects on the negative symptoms of schizophrenia are postulated to 
relate to dopamine turnover in the prefrontal cortex. This can be modulated by combined 
D2 and serotoninergic 5-HT2A receptor antagonism, partial D2 receptor antagonism or the 
preferential blockade of inhibitory dopamine auto-receptors (Stahl 2000). This mechanism 
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of serotonergic modulation may be is associated with a beneficial increase in striatal 
dopamine release as observed in imaging studies (Dewey, Smith, Logan, Alexoff, Ding, 
King, Pappas, Brodie and Ashby 1995). This hypothesis is discussed in detail by Horacek 
and colleagues (Horacek, Bubenikova-Va1esova, Kopecek, Pa1enicek, Dockery, Mohr and 
Hoschl 2006). 
Mécanisme d'action des ISRS 
SSRIs selectively targeting serotonin receptors were developed based on the 
hypothesis that alterations in receptor sensitivity may play a role in both the efficacy of 
antidepressant drugs and the pathophysiology of depressive-like symptoms (e.g., negative 
symptoms), (Feighner 1999). These agents, which include fluoxetine, paroxetine, sertraline, 
fluvoxamine, and citalopram, has shown higher efficacy to their older counterparts (MAOI, 
TCA) with a lesser side effect profile. The SSRI class of drugs has a wide range of clinical 
applications in the full spectrum of depressive disorders and in many other psychiatrie 
disorders (Maina, Albert, Salvi and Bogetto 2004; Reist, Nakamura, Sagart, Sokolski and 
Fujimoto 2003). 
Potent 5-HT2 blockers were seen to Improve secondary negative symptoms by 
simply reducing the EPS. SSRI increases serotonin levels at the synapse stimulating a large 
number of serotonin receptors subtypes and perhaps with various interactions with 
dopamine receptors, which is postulate to be the underlying their antidepressant potential 
(Stahl 2000). Two mechanisms of action which are of interests in generating antidepressant 
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efficacy lies in, firstly that increased levels of serotonin occur after desensitization at the 
dendritic 5-HTla receptor and terminal 5-HTld receptor. Secondly, SSRIs may be are 
down-regulating postsynaptic 5-HT2a receptors (Berman, Sporn, Belanoff, Schatzberg and 
Charney 2004). 
Base neurobiologique des symptômes négatifs 
Burden of negative symptoms in schizophrenia is clinically associated from alogia 
(poverty of speech and its content; blocking; increased latency of response interest), 
avolition-apathy (impaired grooming and hygiene; lack of perseverance at work or school 
dependency on others to structure; physical anergia activities), anhedonia-asociality 
(decreased recreational interests and activities; decreased sexual interest and activity, 
decreased ability to feel intimacy, new experiences and closeness; decreased relationships 
with close and distant acquaintances), flat affect or blunting (monotonous facial expression 
associated with socialization, recreation, decreased spontaneous movement productivity, 
initiative, perseverance; paucity of expressive gestures and curiosity; poor eye contact; 
affective non-responsiveness; inappropriate affect; lack of vocal intlection positive and 
negative events), and attentional impairment (work inattentiveness; inattentiveness during 
mental status testing) (Sadock and Sadock 2003). 
Structural changes are observed in schizophrenia patients with negative symptoms. 
These symptoms may be due to alterations in the micro circuitry in the brain, specifically 
t~e right insular region of the fronto-temporal region (Shin, Kwon, Ha, Park, Kim, Hong, 
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Moon, Lee, Kim, Kim and Chung 2006). Other studies report on various structural changes 
including 1) enlargement of the lateral ventricles (Andreas en 1982; Andreasen, Ehrhardt, 
Swayze, Alliger, Yuh, Cohen and Ziebell 1990a; Andreasen, Swayze, Flaum, Yates, Arndt 
and McChesney 1990b; Marks and Luchins 1990) 2) third ventricle, 3) smaller temporal 
lobe, 4) hippocampal, and superior temporal gyral volume (Flaum, O'Leary, Swayze, 
Miller, Arndt and Andreasen 1995). From a metabolic standpoint, these symptoms were 
reported to be negative1y linked (decreased activation) with regional cerebral blood flow in 
the nucleus 1enticularis, prefrontal cortex, and the temporal cortex (Andreasen, Rezai, 
Alliger, Swayze, Flaum, Kirchner, Cohen and O'Leary 1992). In tandem, Liddle and 
colleagues (Liddle, Friston, Frith, Hirsch, Jones and Frackowiak 1992) studied these 
symptoms under positron emission topography and found decrease in blood metabolism in 
the prefrontal and left parietal cortex and heighten activity in the caudate nuc1ei. 
There is no evidence that damage to any one structure, pathway or region is 
uniquely responsible for producing negative symptoms. Instead, a network of cortical and 
sub-cortical are as is implicated, within which, damage, dysfunction or abnormal cerebral 
circulation, and neuronal metabolism lead to an increased probability of the incidence of 
these symptoms (Frith, Friston, Herold, Silbersweig, Fletcher, Cahill, Dolan, Frackowiak 
and Liddle 1995; Keightley, Seminowicz, Bagby, Costa, Fossati and Mayberg 2003). These 
connectivity theorists suggest that various elements are at play in the control of negative 
symptoms of schizophrenia including: 1) alteration in the motivation system (limbic-
ventral-striatopallidal system) (Seeman 2001); 2) changes in the dopamine system (striato-
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thalamo-cortical circuits) (Kane and McGlashan 1995); 3) degeneration of the ventral 
tegmental area (Castner, Williams and Goldman-Rakic 2000); 4) alteration in the reward 
system (mesolimbic) (Bressan, Erlandsson, Jones, Mulligan, Flanagan, Ell and Pilowsky 
2003; Pycock, Kerwin and Carter 1980); 5) change in the cholinergic-dopaminergic system 
(Laruelle, D'Souza, Baldwin, Abi-Dargham, Kanes, Fingado, Seibyl, Zoghbi, Bowers, 
Jatlow, Chamey and Innis 1997; Tandon and Greden 1989; Tandon, Shipley, Greden, 
Mann, Eisner and Goodson 1991); 6) Glutamate (cortico-cortical; cortical-basal ganglia and 
cortico-limbic) (Lahti, Holcomb, Medoff and Tamminga 1995). These systems are 
discussed by Brown and Pluck (Brown and Pluck 2000). 
From a fundamental neuro-scientific point of view, Weinberger and Berman 
(Weinberger and Berrnan, 1996) suggest that these symptoms are associated with 
dopaminergic hypoactivity in the PFC. However, others report a correlation between 
increase in cerebral ventricular size and persisting negative symptoms (Potkin, Weinberger, 
Linnoila and Wyatt 1983). In the contrary, Pickar and group (Pickar, Breier, Hsiao, Doran, 
Wolkowitz, Pato, Konicki and Potter 1990a) found a lower concentration of 5-hydroxy 
indole acetic acid in schizophrenia patients. Therefore there is no clear consensus on the 
implication of change in the ventricular system and the negative symptoms. 
Hence, one possible reason for this treatment approach is that, from a molecular 
view, dopaminergic and serotonergic systems interact in the PFC and endogenous 5-HT can 
enhance dopamine release in the nigro-striatal pathway (Pickar, Litman, Konicki, 
Wolkowitz and Breier 1 990b; Yadid, Pacak, Kopin and Goldstein 1994), it is possible that, 
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when added to first generation antipsychotics, SSRI may increase dopamine levels in PFC, 
specifically, increasing extra-cellular fluid dopamine levels in the mPFC as seen in rodents 
(Csemansky, King, Faustman, Moses, Poscher and Faull 1990; Jibson and Tandon 1998; 
Meltzer 1989; Zhang, Perry, Wong, Potts, Bao, Tollefson and Bymaster 2000). However, 
with regards to second generation antipsychotics, although paradoxical, the serotonergic 
antagonism potential seems to be the key element (Meltzer 1992). The paradox lies in 
adding an SSRI, a serotonin agonist, to an antipsychotic with serotonin agoni st properties. 
In addition, as to whether serotonin neurotransmission causes the negative symptoms, or 
negative symptoms are related to se roto nin-dopamine interaction in the ventral tegmental 
area, remain another link to a difficult question. However, other neurotransmitter systems 
such as glutamatergice and cholinergie may be involved in inducing negative symptoms. 
Therefore, dopamine-serotonin interaction may only be part of a more complex system 
(Miller and Tandon 2001). 
In conclusion, by blocking 5-HT2A and D2 receptors, a higher affinity for 5-HT2A 
receptors than for D2 receptors is created which leads to lower risk for EPS. Altematively, 
5-HT2A1D2 receptor antagonism increases the dopamine release to the PFC and striatum, 
and thus it becomes one of the therapeutic potential of the negative symptoms. This action 
is also valid for partial dopamine receptor agonist with 5-HT2A antagonism (such as 
aripiprazole), 5-HTIA receptor agoni st and blockade of D2 receptors that increases 
dopamine release to the PFC, striatum and limbic structures. In addition, the blockade of 5-
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HT2C receptors and blockade of D2 receptors acts in concert to block 5-HT2A receptors. 
Moreover, blockade of alpha-adrenoceptors and D2 receptors includes alphal-adrenoceptor 
antagonism, decreases activity of serotonin projections, and in combination with D2 
receptor blockade would mimic 5-HT2A/D2 receptor antagonism, which is Similar to 
alpha2-adrenoceptor (Horacek, Bubenikova-Valesova, Kopecek, Palenicek, Dockery, Mohr 
and Hoschl 2006). 
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Synthèse des études 
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This meta-analysis consists of eleven (N=11) robust clinical trials, included in our 
meta-analysis (Sepehry, Potvin, Elie and Stip 2007) table 1. Other researchers have 
reviewed this treatment approach on several occasions. Starting with Evins and Goff in 
1996 (Evins 1996) who briefly addressed SSRI add-on treatment in their review paper on 
adjunctive antidepressant drug therapy for negative symptoms of schizophrenia. Sproule, et 
al in 1997 (Sproule, Naranjo, Brenmer and Hassan 1997) reviewed SSRI's 
pharmakodynamics on the Central Nervous System (CNS), and Zullino, et al (2002) 
(Zullino, Delacrausaz and Baumann 2002) investigated the status of SSRI add-on therapy 
approach in schizophrenia. A complete review consisting of the pharmacokinetics and 
pharmakodynamics of the SSRI add-on treatment was conducted by Henry Silver (Silver 
2004). A recent systematic review on antidepressant add-on therapy for persisting negative 
symptoms has been carried out by Rummel and colleagues (Rummel, Kissling et al. 2005), 
showed that antidepressants in general were of potential bene fit to schizophrenia patients. 
However, our result with Il studies specific to SSRIs shows the contrary. Moreover, other 
studies were also published on the topic that we considered inconclusive regarding this 
treatment approach. Ultimately, the se studies; case reports, open trials and cross-over 
designs were dropped out from our meta-analysis. The exclusion of the cross-over studies is 
discussed in our recent publication (Sepehry, et al 2007) and later in the discussion section. 
That leads us to the appraisal of few open trials, case reports, and two randomized, placebo-
controlled studies, published after 2004. The randomized studies were one with 
fluvoxamine (Chaichan 2004) and the other with paroxetine (Jockers-Scherubl, Bauer, 
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Godemann, Reischies, Selig and Schlattmann 2005) as co-treatment for persisting negative 
symptoms. 
The study by Chaichan (Chaichan 2004) was a short term 6-week trial that 
investigated the efficacy and adverse effects of fluvoxamine add-on to olanzapine 
compared to ol~nzapine alone, in twenty patients suffering from acute exacerbation of 
schizophrenia. They assessed efficacy with the Brief Psychiatric Rating Scale (BPRS) and 
side effects with the Udvalg for Kliniske Undersogelser (UKU) side-effect scale. They 
reported significant changes in the total means of BPRS and the general psychopathology 
score in the add-on treatment arm (P = 0.037 and P = 0.045, respectively). This study was 
excluded from our meta-analysis, given the fact that BPRS is not specifically designed to 
detect negative symptoms changes in patients suffering from schizophrenia. Nonetheless, 
authors suggested that their findings are of value, given the fact that in a combined 
treatment approach, the medication was well tolerated and more effective than 
monotherapy. 
The second trial by Jockers-scherubl' group (Jockers-Scherubl, Bauer et al. 2005) 
was a double-blind, 12-week long-term study attempting to replicate their previous positive 
findings. They carried-out this trial with 30mg of paroxetine co-administered with 
antipsychotics, in comparison with a placebo group to treat negative symptoms in chronic 
schizophrenia patients (n=29), even though there is no definition of the criteria of 
chronicity in schizophrenia. The authors screened the patients using Positive and Negative 
Syndrome Scale (P ANSS), and later with the Hamilton Depression Scale (HAM-D) and 
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scales for extrapyramidal side-effects. With close to 14 % attrition, they opted for an 
intention-to-treat (ITT) analysis based on the 25 patients who were present for at least one 
follow-up assessment, and analyzed their data by the mean of last observation carried 
forward (LOCF). With a fairly naturalistic method, they reported a decrease in PANSS-
negative subscale mean score in both groups. This change was reported to be significant 
between groups (paroxetine vs. placebo) but the mean depression scores were almost 
constant. Nonetheless, they recommended use of paroxetine for treatment of negative 
symptoms in chronic schizophrenia. 
Other studies of open trials were methodologically weaker (Silver, Kushnir and 
Kaplan 1996; Takahashi, Sugita, Higuchi and Shimizu 2002), as were case reports (Silver, 
Jahjah and Kushnir 1995; Silver, Kaplan and Jahjah 1995); and studies with mixed patient 
types (Bondolfi, Eap, Bertschy, Zullino, Vermeulen and Baumann 2002). 
The case reports by Silver and colleagues were on fluvoxamine add-on treatment 
that led to modest clinical improvement, taking into consideration psychotic as weIl as 
negative symptoms. Furthermore, an open pilot study by Silver et al, with the same SSRI 
add-on medication, reported a decrease in negative symptoms score on SANS and so 
concluded that these agents may be potentially effective in the treatment of schizophrenia 
patients with persisting negative symptoms. 
Bondolfi et al (Bondolfi, Eap et al. 2002) presented another open label short trial 
(during 30 days), showing the positive effect of fluoxetine combined therapy (20mg/day 
from day 6) in mixed type psychotic inpatients (e.g., schizophrenia, schizoaffective, 
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schizophreniform disorder) O'l"=l1). They investigated pharmacokinetics and safety of this 
compound in combination to Risperidone (4 or 6 mg/day), and have assessed negative 
symptoms with PANSS-negative subscale. They reported 91% of their patients' 
demonstrated clinical improvement, defined as a reduction of 20% or more in symptoms 
and 70% on depressive like symptoms compared to the baseline. The depression symptoms 
were tested with Montgomery-Âsberg Depression Rating Scale (MADRS). Further, they 
noted non-significant change in severity and incidence of extrapyramidal symptoms, and 
adverse events, in the co-administration arm of their trial. This study was not included in 
our meta-analytic study because of mixed patient type. 
Another open label trial, Takahashi et al. (Takahashi, Sugita et al. 2002), in a 12 
week period, investigated the efficacy and safety of co-administration of fluvoxamine to 
risperidone for the treatment of residual positive and negative symptoms in chronic patients 
with schizophrenia (N=30). They had no attrition. They have evaluated symptoms with 
P ANSS and extrapyramidal symptoms with Simpson-Angus extrapyramidal effects (S-A) 
scale. During the trial, they have observed no significant change in any P ANSS sub-scales 
or in S-A scale of their patients, and so consequently concluded that fluvoxamine is 
ineffective as a co-treatment agent for chronic schizophrenia patients. 
Although Kasckow and associates' study (Kasckow, Mohamed, Thallasinos, 
Carroll, Zisook and leste 2001) was published before 2004, it was missed from other 
reviews. This perhaps suggests to reviewers' potential bias. Kasckow and colleagues 
investigated citalopram (20-40 mg/day) add-on treatment over a 10 week single blind trail. 
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Their study included both middle-aged and elderly chronic schizophrenia patients (N=19, 9 
were randomly assigned to the active treatment arm). The peculiarity to their study was that 
their sample consisted of sorne patients receiving typical (Haloperidol, Fluphenazine, 
Thioridazine) and sorne atypical (Olanzapine, Risperidone, and Quetiapine) antipsychotics. 
Patients were tested both at baseline and at the end of the trial with a 17-item Hamilton 
Rating scale for Depression (HAMD), for depressive symptoms and, PANSS and Clinical 
Global Impression (CGI) scale for general symptoms, however, the raw scores for PANSS 
were not provided in their study. The author reported amelioration in both positive and 
negative symptoms with no side effects; in addition, the active treatment arm demonstrated 
superior performance in HAMD and on CGI scale than the comparison group. The author 
reminded that their findings are only preliminary and further controlled trials are warranted. 
This study was also excluded from our meta-analysis for two reasons, first due to the fact 
that it was the only study explicitly stating that it was a single blind trial, and second, for 
including patients receiving both atypical and typical antipsychotics in the active treatment 
arm. 
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There are inconsistencies in research results regarding the co-prescription of 
antipsychotics with SSRI. While sorne studies report positive results using poly-pharmacy, 
others report negative results. 
The positive results that emerge from adjunctive conventional antipsychotics 
include the use of fluvoxamine (Silver and Nassar 1992; Silver and Shmugliakov 1998; 
Silver, Barash, Aharon, Kaplan and Poyurovsky 2000) and fluoxetine (Goff, Midha, Sarid-
Segal, Hubbard and Amico 1995). The negative results on the other hand were obtained 
from the study of Arango and collaborators using various antidepressant (Arango, 
Kirkpatrick and Buchanan 2000) and Buchanan and colleagues (Buchanan, Kirkpatrick et 
al. 1996) using fluoxetine, Lee (Lee, Kim et al. 1998) using serteraline, and Salokangas and 
coworkers (Salokangas, Saarijarvi, Taiminen, Kallioniemi, Lehto, Niemi, Tuominen, Ahola 
and Syvalahti 1996) using citalopram. Simply evaluating the possibilities among random 
and double blind studies, fluvoxamine tends to produce more positive result than the other 
antidepressants when given with conventional antipsychotics. All of the studies evaluated 
negative symptoms of schizophrenia ranged from short to medium-term treatment duration 
(e.g., 2 to 12 weeks). 
Studies with various range of treatment duration provided different conclusions 
[refer to Szegedi, Anghelescu, Wiesner, Schlegel, Weigmann, Hartter, Hiemke and Wetzel 
1999; Hiemke, Peled, Jabarin, Hadjez, Weigmann, Hartter, Modai, Ritsner and Silver 
2002]. One of the limitations of these studies was insufficient sample size, which renders 
generalization difficult, hence lowers the statistical power (Buchanan, Kirkpatrick et al. 
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1996; Hiemke, Peled et al. 2002; Takahashi, Sugita et al. 2002). Usages of other drugs such 
as, anticonvulsant, lithium, or anticholinergic, in cases of parkinsonism-like symptoms 
were not fully reported. 
Most studies use clozapine with adjuvant antidepressant treatment. It is believed 
that clozapine is used mostly in cases of patients that are "chronic" as well as unresponsive 
to other atypical antipsychotics. There are limited reports of comparison groups in those 
studies to placebo (refer to Buchanan, Kirkpatrick et al. 1996; Kasckow, Mohamed et al. 
2001). Buchanan and group (1996), and Kasckow and colleagues (2001) final observation 
of, a non significant negative symptoms improvement, is unreliable due to the testing 
variability (e.g., BPRS, PANSS, & SANS). One question cornes to light, and that is, how 
significant is "clinically significant" for these patients suffering from a disproportionate 
amount of disability. Although, these symptom groupings have been integrated initially as a 
norm for diagnosis of schizophrenia in the DSM -IV (Keefe and McEvoy 2001), most of the 
studies have had DSM-Ill-Revised as their diagnostic base, which demonstrate that the idea 
of adjunct SSRI antidepressant to antipsychotic treatment is an old unresolved issue. 
Other factors to consider include the mental state (e.g., chronic or non-
responsiveness) of the patients that has not been fully reported. Another significant factor 
that has been neglected is the relevance of age and duration of illness correlated to 
symptoms improvement. Furthermore, the link between negative symptoms to positive, 
cognitive or affective symptoms has not been fully investigated. Kibel and colleagues 
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(Kibel, Laffont and Liddle 1993) denote a correlation between negative symptoms and 
cognitive deficits. 
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Méta-analyse 
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Qu'est-ce-qu 'une méta-analyse? 
Meta-analysis allows data to be collapsed so that generalization can be made. Meta-
analysis is a quantitative approach using statistical analysis on a collection of individual 
independent studies. Thus, in this manuscript we tend to answer to the following questions: 
1) Why did we do a meta-analysis? 2) How did we apply meta-analytic technics? 3) What 
answer do we have? 4) What is the significance of our findings? 
"Meta-analysis refers to the analysis of analyses. I use it to refer to the 
statistical analysis of a large collection of results from individual studies for 
the purpose of integrating the findings. It connotes a rigorous alternative to the 
casual, normative discussions of research studies which typify our attempts to 
make sense of the rapidly expanding research literature" (Glass 1976). 
In today's language, meta-analysis is considered a new method, a sophisticated 
more objective method than systematic reviews (Glass 1976). The only difference between 
these methods is that a meta-analysis consists of mathematical analysis of the data 
(published or unpublished) that aggregate findings to a common metrics (notably called: 
effect size, effect estimate, or magnitude of treatment effect), allowing the comparison of 
multiple outcomes. The effect size is the strength or the magnitude of the relationship, or 
the degree of departure from the null hypothesis (Rosenthal and Rosnow 1991). Thus, a 
biger effect can be either interpreted as good outcome to a treatment strategy, or the 
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contrary. Yet, meta-analysis is the foundation to decision analysis, which provides data in 
order to evaluate cost effectiveness of different strategies in treatment or approaches (Byers 
and Stullenbarger 2003). In brief, meta-analysis may consist of the amalgamation of a 
minimum of 2 research studies/trials collected, coded, and interpreted using statistical 
methods similar to those used in primary data analysis. Noteworthy, meta-analysis based on 
two research studies can give rise to further discussions. For instance, in terms of treatment 
for the common cold, a meta-analysis based on 2-studies can be considered misleading, 
whereas in for a severe illness, such as malignant glioma with a low prevalence, it can be 
permissible. Therefore, one must be vigilant in interpreting the results of a given meta-
analysis. The results obtained from the meta-analysis are summaries (re-evaluation) of 
studies and exploration of relationships, thus, the meta-analysis is more objective and exact 
compared to a narrative review, with which authors provide a sequence of chronological 
discourse on previous findings (Greenhalgh 1997). By pooling the studies in the meta-
analysis, we increase the power by reducing standard error of the effect size, followed by a 
shrinking of the confidence interval around the effect estimate which in tum increases the 
likelihood of detection of a non-zero population effect. It is noteworthy that a small 
confidence interval elevates the precision of the effect estimate. However, this is relative as 
to whether random or fixed effect models are used (which we will discuss later), since each 
model is sensitive for specific questions under investigation (Cohn and Becker 2003). 
Meta-analysis is known to be an aid to medical and social sciences for decision making 
purposes, resolving conflicting evidence, answering questions where the answer is 
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uncertain, explaining variability in practice or simply to confirm the appropriateness of 
CUITent practice (Higgins and Green 2005). Others note that meta-analysis bridges research 
to clinical practice (Byers and Stullenbarger 2003). 
A good meta-analysis notes of a clear objective necessity and consists of focused 
and sophisticated research trials, while investigating differences in existing studies. It is 
also important to remember that the obtained results are provisional, representing the best 
evidence at the time meta-analysis was conducted, and that these results are subject to 
change in time as more studies are conducted (Mulrow and Lohr 2001). Predominantly, the 
quality of a meta-analysis is only of use and appreciated as the individual studies on which 
it is based. For instance, if the meta-analysis consists of at least one weak study (e.g., open 
label as opposed to ReT), the result is affected. The result of any given study affects the 
result of the meta-analysis. Therefore, even if the meta-analysis is weIl performed on poor 
data, it will still result in a poor outcome. In short, in writing a meta-analytic review, 
simplicity is the key. The following section introduces the meta-analysis method. 
Advant propos 
As stated by O'Rourke (O'Rourke 2006), it appears that the first meta-analysis was 
performed by a British statistician, Karl Pearson in early 1900's. Pearson (Pearson 1904) 
performed this meta-analysis in order to overcome the problem of reduced statistical power 
in studies with small sample sizes. By 1932, the statistical procedure for integration of 
research was followed by Fisher (Fisher 1932) and Bridge (Bridge 1932). 
/ 
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The first medically associated meta-analysis was published in 1955. Sorne years 
later, in the 1970s, a more sophisticated statistical analysis was introduced in educational 
research, initiated by Gene V Glass, an American social scientist. The Oxford English 
dictionary lists the first usage of the term in the statistical context as of 1976. Later, the 
term was interchangeably used with "validity generalization" (Schmidt and Hunter 1977). 
The statistics pertaining to meta-analysis was further expanded by Larry V. Hedges and 
Ingram Olkin, and so was the beginning ofthis concatenating enterprise (Hedges 1983). At 
that time, flaws in meta-analysis were detected (Cooper and Rosenthal 1980). It was then in 
1984 that the future of this versatile and useful approach to scientific research became 
mainstream (Green and Hall 1984). Today, as it was predicted, the literature associated 
with meta-analysis is expanding (Rosenthal 1991). Meta-analytic studies were first key-
worded as meta-analysis in 1977 (Guzzo, Jackson et al. 1987). Meta-analysis was 
introduced in PubMed in 1989. This research approach is sorne tÏmes called, analysis of the 
analyses (Glass 2000), systematic renews, quantitative synthesis, statistical research 
integration, a retrospective look at the data, or testing relationships that had never been 
examined by the primary researcher (Cooper and Hedges 1994). Egger and Smith states, 
that no other term is appropriate than "meta" as other terms are interchangeably used in 
representing other types of findings, or They are not robust at aIl. For instance, "overview" 
is used for traditional reviews, and "pooling" incorrectly implies that the source data are 
merged (Egger and Smith 1997). However, the actual term, meta-analysis was first 
suggested by Michael Scriven's meta-evaluation (evaluation of evaluations) in 1969 
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(Stufflebeam 2001). So today, the term "validity generalization" no longer implies to meta-
analysis but to a special application of meta-analysis. Additional developments led to the 
establishment of the Cochrane collaboration (http://www.cochrane.org/) in 1992 for health 
care system (Egger and Smith 1997; Geddes, Freemantle, Streiner and Yarnolds 1998), and 
in 2000 the international Campbell Collaboration (http://www.canlpbellcollaboration.orgl) 
for social, behavioral, and educational arena. These organizations both carry an online 
library that creates a high-standard in conducting meta-analysis studies available for use by 
clinicians and the general population. In many fields, meta-analysis is weB accepted as the 
preferred methodology for summarizing literature. Today, according to Ceballos and 
colleagues (Ceballos, Garcia-Campayo, Artal and Valdizan 2001) psychiatry is the medical 
specialty in which more studies on meta-analysis have been carried out. Consequently, their 
impact on clinical practice is scarce, or in other words, no evidence-based approach is at its 
infancy. To help in sound clinical practice, and provide better decision making with regards 
to symptom control and functioning enhancement, meta-analysis of negative symptoms 
with uncontrolled outcomes has lead to greater power detective of effects. In schizophrenia 
research in particular, the heterogeneity of symptoms, variance in assessment, and 
differences in treatment approach, make results difficult to generalize. 
Principes fondamentaux de méta-analyse et de statistiques 
In a given amassed set of studies, the number of trials with a low sample size (e.g., 
ranging between 20 and 75 total enrolled research subjects) with minimal precision and 
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power to increase the applicability of the findings, is problematic. Although we have 
mentioned before, it is of value to repeat this notion in this context. By aggregating the 
sample size of the clinical trial studies in the meta-analysis, we increase the power by 
reducing standard error of the effect size, followed by the shrinking of the confidence 
interval around the effect estimate which in tum, increases the likelihood of the detection of 
a non-zero population effect (Hedges and Vevea 1998). It is noteworthy to realize that, 
small confidence intervals elevate the precision of the effect estimate. However, this is 
relative to whether the random or fixed effect model is used, because each model is 
sensitive for specific question under investigation (Cohn and Becker 2003). 
Compared to literature reviews, meta-analysis is more accurate and less subjective; 
and in comparison to smaller studies, in which the role of risks can not be detected, meta-
analysis can point to them. 
Méthodes de méta-analyse 
There are 3 major approaches to meta-analysis: 1) vote counting or binary outcome, 
2) combining significance levels, and 3) combining estimate of effect sizes. 
The first approach, using the non-parametric statistics (e.g., odd-ratio (OR), relative 
risk (RR)) has severallimitations (Gurevitch and Hedges 1999). First, it may fail to identify 
a true treatment effect that may be important clinically; second, it considers every study 
equally, no matter of the sample size; third, it does not provide with a useful estimate of 
the magnitude of an effect across a group of studies (Freemantle and Geddes 1998). 
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The second method, combining the significant effect has its own limitations. 
Initially, important data such as me an, standard deviation, and the sample size that are used 
as the raw data are missed. Then, the reported significant level is an estimate that does not 
take the sample size in to consideration. Therefore, the weighting of the effects would be 
inappropriate. Furthermore, combining the effect estimate per study would not give a 
precision on the strength or weakness of the effect obtained, particularly in cases of 
variability and weight of studies. Another caveat to this method is that in cases of non-
significant results in many studies, the degree of significance is not reported, which leads to 
publication bias. This notion will be discussed later. 
In this manuscript we elaborate notably on the third statistical method, the 
combining of the effect estimate, mainly using parametric tests such as Cohen's d or 
Pearson's r. This last approach which was developed by Glass et al (Glass, McGaw and 
Smith 1981) and Hunter et al (Hunter, Schmidt and Jackson 1982), to this day, is regularly 
used. Qualitative steps required for a meta-analytic approach such as collecting and 
classifying data (coding), before implementing meta-analytic data-analysis and 
interpretation are noted in the following sections. 
In every meta-analysis, the investigator starts with summarizing the data for each 
study and computes the effect size. For example, if a study reports means and standard 
deviations, one computes the standardized mean difference and the variance for each effect 
size. 
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Stratégies de recherche 
In a given meta-analysis, sever al search strategies are of importance; notably, 
searches of the electronic engines (e.g., PubMed, PsychINFO, Excerpta Medica dataBase 
(EMBASE)) on various platforms (e.g., OVID), which is then enhanced by hand searches 
Uournal by journal, conference proceedings, and cross-referencing with other reviews and 
reference lists) (Pai, McCulloch, Gorman, Pai, Enanoria, Kennedy, Tharyan and Colford 
2004). In regard to clinical trials, pharmaceutical companies are also contacted in order to 
collect the unpublished data. It is imperative to note, that this approach in later years would 
be less implemented by the advent of the new development in registering clinical trials, 
since clinical trials registration ameliorates access to unpublished data. It is noteworthy 
that, in the awareness of missing data, in the emerging studies, authors can be contacted to 
collect further pertinent information. These methods are used in order to gather maximum 
data to rule out a decision, based on minimal prejudice, and high sensitivity and specificity 
(McManus, Wilson, Delaney, Fitzmaurice, Hyde, Tobias, Jowett and Hobbs 1998). 
Recherche par voie électronique 
Starting with the relevant search engines, meta-analytic authors will use key words 
specific to the meta-analysis' question. The key words are usually generated by the expert 
in the field, and are usually descriptive of the type of the people (healthy or ill), type of the 
treatment or intervention (psychological or medical), and type of the effect of interest. 
These keywords are sometimes extensively expanded through usage of a thesaurus, usually 
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provided at each search engine. In the context of psychiatric and mental illness combined 
with pharmaceutical treatment, PubMed, PsychINFO, EMBASE, Cochrane trial register, 
Australasian medical index, and CUITent Content are usually investigated. This approach is 
not inclusive, and may contain a selection of other search engines. It is believed that there is 
a 30 to 70% overlap between databases (Dickersin, Scherer and Lefebvre 1994); hence, an 
organized in-house database cleared of the overlaps is a must. It is crucial to specify that 
the next section, hand-searching, is time consuming. Notably, few published meta-analysis 
follow this rule or report such performance. For instance, Guzzo and colleagues report that 
the electronic or computer searches are of convenience and are frequently understood to be 
more exhaustive than manual search, and have the potential to be exceedingly reliable 
(Guzzo, Jackson et al. 1987). It is important to know that, simply relying on abstract 
reviewing, as they are the first to be coUected via electronic engines, would raise the chance 
of failing to collect important studies that would have been otherwise detected via 
reviewing of full articles (Potvin, Sepehry and Stip 2007). 
Recherche manuelle 
In order to gather the maximum number of studies (Dickersin, Scherer et al. 1994), 
journal by journal searches, cross-referencing, or by the mean of snowball procedure 
(Mullen 2003; Davis 2004) searching each article's reference list should be undertaken. 
Precise1y, manual searching should be undertaken by covering gray literature (unpublished 
and difficult to retrieve studi~s, for instance dissertation abstracts or reference proceedings), 
thus controlling for the file drawer effect. Hand searching, in addition to searching 
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electronic databases, for instance Medline, has been reported to be of higher efficacy 
(Hopewell, Clarke, Lusher, Lefebvre and Westby 2002). For example, with regards to 
schizophrenia, peer reviewed journals such as Schizophrenia Research and Schizophrenia 
Bulletin are the main joumals that usually meta-analytic authors tend to use to conduct a 
hand-search. Another method used to conduct a hand search is by considering the high 
frequency of the occurrence of a given journal in the database, in order to be used for this 
procedure. One example for utilization of this method is in the meta-analysis of the effect 
of antipsychotic medication on long-term memory pub li shed in Journal of 
Psychopharmacology (Thomton, Van Snellenberg, Sepehry and Honer 2006). The cross-
referencing is usually carried-out with published reviews, including references listed at the 
end of each article. 
Codage 
The coding is a method to categorize studies with a set of a priori selected criteria, 
and hypotheses. This is to either systematically shrink (collapse) or lump together the 
gathered literature. The coding is used to delineate the types of research that are most 
appropriate to answer a particular question (Mulrow and Lohr 2001). This method is 
usually carried-out in collaboration with the authors to avoid aIl preconceived notions 
(biases) in study selection, and to diminish inter-rater and intra-rater disagreement. The 
coding is also used in order to assess the quality of research studies. A coding sheet or 
coding book usually accompanies the datalresults (Brown, Upchurch, Anding, Winter and 
Ramirez 1996; Potvin, Sepehry and Stip 2006) (refer to the Appendix section). Sometimes 
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this is omitted, because of low number of studies enrolled in the meta-analysis. The coding 
is used precisely to determine which variable(s) has a moderating effect on the primary 
effect estimate, and enhances strategies for better research design (Brown, Upchurch and 
Acton 2003). In coding, pre-determined inclusion and exclusion criteria are set, and later, 
the studies are ranked based on their particularity, or on an in-house coding form. Each 
coding method may consist of categories pertaining to methodology (e.g., washout, 
baseline, end-point), study design (e.g., random, double blind, parallel controlled arm 
design), intervention description (e.g., type of antipsychotics: typical or atypical), and 
outcome measures (e.g., PANSS or SANS or Scale for the Assessment of Positive 
Symptoms -SAPS). 
It is important to make a reference to the pooling versus combining in meta-
analysis. The simple pooling of data is used to provide an overall summary of subgroup 
data or data from a number of related studies, which pay no attention to the distinctiveness 
of the sub-groups or individuals (Bravata and Olkin 2001). The combining of the data on 
the other hand, is used to put together subgroups or individual studies after they are being 
weighted. 
Critères d'exclusion & d'inclusion 
The criteria are adapted, specifically, to the clinical and research question which can 
be revised accordingly (e.g., iftoo few or too many studies are obtained, provided that care 
is taken to avoid making changes that would introduce bias). These criteria usually consist 
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of characteristics su ch as age, gender, population of study, and intervention of interest 
(SSRI add-on treatment for instance), then further limited to the language of the studies 
(e.g., English or French for instance). These standards are used to simplify identification of 
cognate studies that are consistent to the investigated hypothesis. The decision on exclusion 
and inclusion of studies is usually taken independently with two or more authors in order to 
decrease the likelihood of an occurrence of an error. If the decision among authors is not 
concordant, a consensus must be reached before any analysis is undertaken. 
A good example of exclusion criteria is the relevance of population of study. 
Authors aim at weeding out articles that are not pertinent to the original question of study. 
For example, authors searching schizophrenia studies can limit select studies to patients 
suffering from schizophrenia and reject studies with patients suffering from schizophrenia-
like symptoms. For instance, in our published study, the randomness, blindness of the 
participant and investigator, and the experimental design were the factors of interests. 
Biais de publication 
The basic concern with publication bias may results from unpublished data. Studies 
that report relatively large treatment effects are more likely to be submitted and/or accepted 
by the journals than studies which report more mode st treatment effects. On the other hand, 
smaller studies get the chance to be put at display in the conferences, so, it is the 
responsibility of the meta-analyst to in corporate studies from numerous sources other than 
journal articles alone. Since the treatment effect estimated from a biased collection of 
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studies would tend to overestimate the true treatment effect (committing either of type l or 
II error), it is important to assess the liable extent of the bias, which has a great potential to 
impact on the conclusions and statistically threat the validity (Moller and Jennions 2001). 
Sorne of the possible biases in a given meta-analysis, for instance, are sampling, selection, 
and within study bias (Gallus and Leandro 2005). 
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Évaluation de la qualité des études 
Quality assessment in meta-analysis is important. This is because we aggregate 
multiple trials that don't have common hypotheses in mind, or are conducted in different 
countries, have differing protocol, or ethical requirement. To be more specific, we have to 
conduct quality assessment of the trials to minimize impartiality in conducting the 
quantitative systematic review, gain insight into potential comparison, and guide 
interpretation of the findings. Although interpretation of the findings has to be limited -
simply to report on what the literature says, and not what it may suggest - there are meta-
analytic studies that fail to follow this golden rule. There are several factors that warrant 
quality assessment, for instance, including applicability of the findings (external validity), 
validity of studies, and trial designs characteristics (e.g., random vs. non-random) all of 
which affect the interpretation of the results. To date, there are more than 25 scales 
proposed for quality assessment of clinical trials (Moher, Jadad, Nichol, Penman, Tugwell 
and Walsh 1995; Moher, Jadad and Tugwell 1996). Sorne good examples would be scales 
developed by Jaded, et al (Jadad, Moore, Carroll, Jenkinson, Reynolds, Gavaghan and 
McQuay 1996), Cochrane for trial design assessment, or Chalmers and colleagues 
(Chalmers, Smith, Blackburn, Silverman, Schroeder, Reitman and Ambroz 1981). It is 
noteworthy that only Jadad and colleagues' scale is scientifically validated (Verhagen, de 
Vet, de Bie, Boers and van den Brandt 2001). 
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"Funnel plot" 
Publication and other forms of selection favoritisms pose a threat to the validity of 
meta-analysis; hence, several methods to investigate this issue are undertaken. For instance, 
Funnel plot which, first was introduced by Light and Pillemer (Light and Pillemer 1984), is 
meant to detect such biases (Egger, Davey Smith, Schneider and Minder 1997). It is noted 
by Begg and Berlin (Begg and Berlin 1988) that funnel plot is the preferred informaI 
mechanism for recognizing these types of biases. Funnel plot (scatter plot) is graphed by 
scheming of the trial-specific effect versus a measure of its precision. Presence of 
asymmetry in the plot suggests for preval en ce of biases, or systematic dissimilarities 
between smaller and larger studies (Tang and Liu 2000). On the other hand, the non-biased 
structure of the plot is a point which is symmetrically scattered around the omnibus effect 
in the shape of an inverted funnel (Egger, Smith, Schneider and Minder 1997). And so, in 
the absence of bias, effect estimate from small size trials will scatter widely at the bottom 
of the graph, with the spread narrowing among larger studies (Stem and Harbord 2004). 
In general, the funnel plot is a graphic representation of a measure of study size 
(usually standard error or precision) on the vertical axis as a function of effect estimate on 
the horizontal axis. Usually, bigger trials appear near the top of the graph, and tend to 
cluster closer to the mean effect size. Smaller size trials appear toward the bottom of the 
graph, and (given that there is greater sampling variation in effect size estimates of the 
smaller size trials), these effect sizes are expected to be dispersed across a range of values. 
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"Fait-sale N" 
The classic fail-Safe N and the Orwin fail-safe N (Orwin 1983) procedures were 
developed to ask if we need to be concemed with the yielded effect estimate that may 
perhaps be an artifact of bias. The issues with publication bias lies in the ground that 
possibly a quantity of non-significant studies are missing from our omnibus analysis and 
that these studies, if included, would change the observed effect. Rosenthal (Rosenthal 
1979) suggests that, we ought to compute the number of studies that would be required to 
nullify (changing in the opposite direction) the effect. If this number is relatively small, 
then there is undeniable foundation for concem. However, if this number is large enough 
(although subjective, relative to the total number of trials included); we can be confident 
that the yielded effect, while possibly inflated by the exclusion of sorne trials, is 
nevertheless not zero. What's more is that he also suggested this analysis be called a 'file-
drawer' analysis, given the fact that file drawers being the alleged location of the missing 
studies. Later, Cooper proposed 'Fail-Safe N'as a term referencing to the nùmber of 
missing studies/trials that would void the effect (Cooper 1979). 
This approach has limitations (Hsu 2002). Initially, it presumes that the effect 
estimate in the hidden studies is zero, rather than considering the probability that a quantity 
of the studies/trials may well provide an effect estimate in the opposite direction. 
Accordingly, the number of trials essential to make this effect useless, the yielded effect 
estimate may be far smaller than the suggested Fait-Safe N. AIso, this approach 
concentrates simply on statistical rather than clinical significance. That is, it possibly 
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provides us with the chance to emphasize that the yielded treatment effect is not zero, but it 
does not address the question of whether in light of clinical investigation, it remains 
clinically important after the omitted trials have been incorporated. In addition, although, 
the notion of sm aIl and large is very subjective, and there is no consensus in the literature 
on the numbers included in each category, there are meta-analyses using this conventional 
fail-safe method. We can nevertheless note that the fail-safe N algorithm is based on 
computation of p-value for each study, and their summation. On the contrary, the 
commonly established method, computes an effect size for each study, combines the effect 
sizes, and then computes the p-value for the combined effect. The two methods, the 
classical fail safe and omnibus effect estimate calculation, do not normally yield matching 
results. Whereby, total abandonment of the technique in favor of the more optimal methods, 
such as Orwin fail-safe N, Duval and Tweedie's Trim and Fill, etc, is suggested. 
Like the classic fail-safe N, the Orwin fail-safe N addresses the likelihood that 
studies are omitted from the analysis and that these studies, if included in the analysis, 
would shift the effect size toward the zero effect. Yet, it is different from the classic method 
in several ways. First, the mean standard differences in means in the new studies (missing) 
can be a value other than zero; and second, the criterion value is an effect size estimate as 
opposed to p-value. That is, the Orwin fail-safe N is the number of (missing) studies that, 
when incorporated in the analysis, will shift the combined standard difference in means, 
past a specified threshold, notably selected by the investigator. This method is sounder, in 
the context of clinical investigation, the author-clinician is able to determine to what degree 
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treatment is effective (provides with room for personal maneuver), although the yielded 
effect estimate is close to zero. 
Further mathematical methods are also available that are not in the scope of this 
manuscript to carry on an elaborative discussion. For instance, for advance mathematical 
techniques, a reference to Egger's Test of the Intercept (linear regression analysis) (Egger, 
Smith et al. 1997; Schulze, Holling and Bohning 2003), or Begg and Mazumdar Rank 
Correlation Test (Begg and Mazumdar 1994; Song, Khan, Dinnes and Sutton 2002), or 
Trim and fill by Duval and Tweedie (Duval and Tweedie 2000; Duval and Tweedie 2000) 
can be suggested. 
Réduction des données 
There are two methods in using key words, to either broadly or narrowly investigate 
the literature. These methods are also called the lumping or splitting. Each has its 
advantages and nuisances. The advantages of the lumping (broadly) are first to avoid 
duplication and second it is informative compared to the other method. Its disadvantages 
are feasibility (time consuming), its compromised complexity, and sometimes mixing 
apples with oranges. On the other hand, the splitting (narrowing) method is easily 
conducted and easily read, yet it is less informative and needs multiple reviews, which limit 
generalization. A good example of this is in pursuing a meta-analysis on the cytokines, 
investigating a single cytokine (e.g., IL-6), versus covering a majority of them (e.g., IL-2, 
IL-6, IL8, IL-lO, etc). 
Calculs méta-analytiques 
Type de données 
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The two main types of data are dichotomous and continuous. In this manuscript, we 
discuss the latter. Other data types are ordinal data, counts and rates, and time to event data. 
For further elaborate explanation to this datum's usage in meta-analysis, a reference can be 
made to Cochrane's handbook (Higgins and Green 2005). 
Statistiques paramétriques - non-paramétriques 
Effect estÏmates can be calculated with several types of data from studies (explained 
in the above section), providing with parametric, or the non-parametric type statistics. It is 
noteworthy that there are mathematical formulas and tables available which will transform 
the odd-ratio to standardized mean difference (SMD) (or Hedges'g) and vice versa. SMD is 
equal to the square roots of 3 divided by n, multiplied by the log of odd-ratio. This helps 
the meta-analyst to pool both types of data. It is of essential value to note that, although 
pooling dichotomous data with continuous data is feasible, one must take into consideration 
the hypothesis in investigation, and thus mixing apples with oranges may have to be limited 
to particular issues. 
The parametric statistic includes statistical data such as standard deviation. In other 
words, we take into account the statistical error in their mathematical formula when 
investigating a certain parameter. The best continuous data for calculating an ES are the 
original individual patients' data, yet, mean, and standard deviation along with sample size 
of the groups are highly valuable and regularly used. Good examples of such statistics are 
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mean changes, analysis of variance (ANOVA) with single degree of freedom, or student's 
t-test. These methods are usually used in the presence of normal data distribution. These 
types of data are also categorized as continuous type data, for instance, scores on a 
depression scale such as beck depression inventory or Scale for the Assessment of Negative 
Symptoms. 
The non-parametric statistics are frequently used when the data is not equally 
distributed, and is usually with smaller sample size. One good example of such statistical 
method is the Mann-Whitney U test or its equivalence, the Wilcoxon rank sum test, where 
the statistical finding relies on the mode (ranking) rather than the median or the mean. This 
category of statistical method pertains to dichotomous data (binary or categorical) (for 
instance, "Yes or No" outcome, as antipsychotic resistant or no resistant). Other examples 
are OR, RR, or risk difference (RD). 
Mesures de la taille de l'effet (2 groupes indépendants) 
Différences normalisées entre deux groupes· 
The weighted difference of the mean is calculated by the following formula: 
Where [cr = ...j [I(X - My / N]]; and where, X is the raw score, cr is the standard 
deviation of a population, I is the sum, M is the mean, and N is the number of cases . 
• For mathematical explanation on how the formulas are driven, please refer to Rosenthal (Rosenthal 1991) 
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Cohen defined d (a descriptive measure) as the difference between the means, 
(Mean, - Mean2) or in the clinical trials (time,- time2, or treatment-placebo, experimental -
control groups), divided by standard deviation (SD) of either group (Cohen 1988). Cohen 
argued that the standard deviation of either group could be used in the calculation when the 
variances of the two groups are homogeneous. 
By convention the subtraction, Meanl - Mean2, is prepared so that the difference is 
positive if it is in the direction of amelioration of the symptoms or in the predicted 
direction, and negative if in the direction of deterioration or opposite to the predicted 
direction. 
However, in practice, the pooled standard deviation, crpooled, lS commonly used 
(Rosnow and Rosenthal 1996), hence the following formula: 
(2) [d= Ml - M2/crpooled] 
Where [crpooled = "[(cr I 2+ crl) / 2] and Power is (8=d"N/2) 
Where, the pooled standard deviation is calculated through the square root of the 
mean square of the two errors (standard deviations) (experimental and control) (Cohen 
1988). That is, the pooled standard deviation is the square root of the average of the squared 
standard deviations (formula· #2). It is important to note that, for similar standard 
deviations, the root of mean square will not fluctuate substantially by simply averaging of 
the two variances. 
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Nonetheless, effect estimate (Cohen 's d) can also be computed from the value from 
at-test (Rosenthal and Rosnow 1991) or an F with 1 degree offreedom. 
In the presence of equal patients or participants, the formula without the n's should 
be implemented. So the following formula is developed in cases of differing n's. In the 
equation # 3, the degrees of freedom for the t-test, is abbreviated as "df', and "n" for the 
number of cases (patients or participants) for each grouping. 
However, Hunter and Schmidt (Hunter and Schmidt 1990) proposed, in the 
existence of equal sample size, utilization of pooled within-group SD provides with lesser 
sampling error than the control SD. They also provide with correction of the effect size for 
measurement error, by the suggesting the following corrective method: 
(4) [Measurement error correction= (ES/ --1r)]. 
Cohen's d can be subsequently computed from r, the ES correlation with the succeeding 
formula: 
(5) [d = 2r / --1(1 - r2)] 
This effect size (d) can be computed from Hedges' g with the following formula: 
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(6) [d = g~(N/df)] 
Hedges' g, another method to calculate the effect size, is an inferential measure. It is 
normally calculated by using the square root of the mean square error from the analysis of 
variance testing for differences between the two groups. Hedges' g is named after Gene V. 
Glass, one of the pioneers ofmeta-analysis. 
Where [s == ~[2:(X - M)2 / N-l]] and [Spooled ~MSwithin] 
Hedges' g also can be calculated from t-test results, investigating differences 
between the two groups (Rosenthal and Rosnow 1991). The formula with separate n's 
should be used when the n's are not equal. Yet, ? is equal to F when df equal 1 in the 
numerator ofF. 
(8) Independent {-test: [g = ~(nl + n2) / ~(nln2)] 
or [g = 2t / -vN] 
or Two-group one way ANOV A: [g=..J F (nI + n2)/ ..J(nln2)] 
The pooled standard deviation (crpooled) can be computed from the unbiased estimator 
of the pooled population value of the standard deviation (SDpooled) and vice versa (Rosnow 
and Rosenthal 1996). 
(9) [crpooled = SDp()oled ~ (df / N)] 
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Where df the degrees offreedom for the MS error, and N = the total number of cases. 
In addition, Hedges' g can be computed from r (the ES correlation) with the 
following formula: 
Glass's delta is another method to compute effect sizes; it is defined as the mean 
difference between the experimental and control group divided by the standard deviation of 
the control group. 
(11) [delta = Mean} - Mean2 / (Jcontrol] 
In the case of missing effect estimate and presence of significance test value, the 
effect size can be calculated (RosenthaJ and DiMatteo 2001). 
(12) [significance test=effect size x study size J. 
Mesures de corrélation de la taille de l'effet « r » 
Correlation measures of effect size r (ES correlation) can be obtained from the t-test 
value with the following formula: 
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(13) [r= ~( ri r+ df)] 
Furthermore, the ES correlation can be calculated from a single degree of freedom; 
F-test value (e.g., a one way analysis of variance with two groups) with the following 
reclpe 
(14) [r= ~[F(1,~ I(F(1,.J + dferror)]] 
Where, the empty U spaces are for the other number (numerator), in degree of freedom 
associated with ANOV A. 
The ES correlation can also be estimated via utilization of Cohen's d or Hedges' g: 
(15) [r= d 1 ~(d2 + 4)] 
And it can be converted to d and vice versa: 
(17) [d= 2r 1 (~1- r 2)]* 
Les modèles: fixe et aléatoire (hiérarchique) 
Test of heterogeneity (e.g., Q-test) in meta-analysis recurrently lacks statistical 
power (The test of heterogeneity is explained later under heterogeneity sub-heading). This 
• In the meta-analytic studies, r 's are typically presented rather than r 
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lack of power is important specifically in the terms of significant heterogeneity. Different 
methods are invented so to facilitate investigation of this variability among studies. 
The fixed effects model developed by Mantel and Haenszel (Mantel and Haenszel 
1959) presumes that there is a distinct fundamental population treatment outcome, which 
will be echoed most accurately by larger size trials with greater statistical power. Fixed 
effects models may unjustly domineer over important differences between studyeffects. 
However, the random effects model (DerSimonian and Laird 1986), on the other 
hand, assumes that the trials are investigating different, hitherto related, treatment results, 
and taking into perspective the variability among studies. This is so, for both the effect size 
estimates and in the distance between the lower and upper tails of the confidence interval 
(Schulze, Holling et al. 2003). This model is considered as flexible, for example, in the case 
of no heterogeneity (p-value of 0.5 or greater), it acts as fixed effects model; however, 
when the p-value shortens, it increasingly takes this into account. Moreover, the random 
effects model increases the weight of smaller studies that are prone to the systematic bias. 
The choice between models remains controversial, although there are reviews on the 
topic reporting that both avoid controversy particularly when they give the same answer 
(Freemantle and Geddes 1998). The random effect model is used principally in the case of 
unexplainable heterogeneity (Higgins and Green 2005). 
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Intervalle de Confiance (CI) 
The confidence interval is the mathematical representation of the variation. It is the 
degree to which the true effect sizes differ across studies. It is ca1culated as the addition of 
sampling error variation with the true variation. The wider the CI (distance between lower 
tail and upper tail), the less accurate is the measured effect estimate, in other words, the 
greater the sampling variability. As a result, interval estimates are sometimes omitted which 
according to Steiger and Fouladi is a sign of embarrassment (Steiger and Fouladi 1997). In 
existence of heterogeneity, CI is wider when the random effect model is used, and on the 
contrary, in the absence of heterogeneity, both models should provide exactly the same CI 
values. 
Report of CI (upper limit and lower limit) in the meta-analytic manuscripts, which 
has its limitations as weIl as its strengths (Cumming and Finch 2001), and it is encouraged 
by the Cochrane. This strength relies on quick elucidation of the results, encourages meta-
analytic thinking, and provides with further information on the precision of the effect 
estimate. Furthermore, the poor overlaps of the CI for the results of individual studies, 
usually signais the presence of statistical heterogeneity. Its weakness lies on its potential 
contribution on the true alpha, the probability of a type 1 error (May 2003). 
Mathematical usage of the CI for means is in the unavailability of the standard 
deviation in the studies: 
(18) [SD= ~ x (upper limit-lower limit)/3.92] 
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In the case oflarge sample size (N)60) at 95% confidence level; 3.92 is the 2 time 
1.96 standard errors for 2 tails. And for smaller sample size, a reference to t-distribution 
values table is necessary to replace the 3.92. 
Hétérogénéité 
Factors leading to heterogeneity can be split into three categories, the clinical, the 
statistical, and the methodological. The clinical heterogeneity is frequently based on patient 
selection, baseline disease severity, techniques utilized, outcomes, and duration of follow-
up. The methodological heterogeneity on the other hand, consists of, randomness in design, 
patient withdrawals, and LOCF (Thompson 1994). The statistical heterogeneity is due to 
variability between continuous type data set (e.g., ANOVA vs. mean and SD). We can 
confirm the presence of heterogeneity in two ways. A common way of indicating the extent 
of heterogeneity is by a statistical test, which is described as Cochran's y) test or the Q-test. 
Another way is the graphical approach (discussed under representation of findings). The 
mathematical formula investigating inconsistency following a Q-test is the 12: 
(19) 12=[(Q-dt) / Q,]*100 
A value supenor to 50% obtained from this formula signaIs a substantial 
diversity/variability in effect estimate of the trials (Higgins, Thompson, Deeks and Altman 
2003). 
64 
The Q-statistic (or Q-test) is a mathematical test that asses ses whether the effects 
produced by a group of studies varies primarily because of sampling error or represents 
systematic differences among the studies in addition to sampling error. A non-significant Q 
indicates possible homogeneity of the effect and a significant point to the heterogeneity of 
the effect (at the 0.05 level or less). If the effect produced by a group of studies is found to 
be homogeneous, then the studies are considered to be from the same population (e.g., 
schizophrenia) and the analysis of the group mean effect is warranted. On the contrary, it 
can be explained that there is a possibility that our group contains two or more distinct sub-
populations of studies (e.g., investigating schizophrenia patient with primary persisting 
negative symptoms vs. secondary negative symptoms). These studies should be further 
subdivided into other categories of variables (e.g., primary or secondary negative 
symptoms) to identify these sub-populations and achieve homogeneity within each group. 
Q-statistic is useful for model testing (fixed or random); in other words, to confirm or reject 
the model chosen by the meta-analyst provides a good fit for the obtained data. Establishing 
homogeneity always cornes before analysis and interpretation of the group means. It is not 
atypical to fail at obtaining homogeneity in sorne or aIl study groupings. In such cases, the 
meta-analyst cannot make confident interpretations regarding which variables or factors are 
contributing to the obtained findings (Grimm and Yamold 1997). 
Significance in Q-test is defined a priori as p< 0.1 (Song, Sheldon, Sutton, Abrams 
and Jones 2001). This test for heterogeneity is considered to have low statistical power 
(Gavaghan, Moore and McQuay 2000), when trials have smaIl sample sizes or are few in 
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number. This explains that although a statistically significant result may indicate a probable 
heterogeneity, a non-significant result must not be taken as evidence for lack of 
heterogeneity. This is also why a p-value of 0.1 0 (a more liberal criterion) is more 
acceptable, than the conventional level of 0.05. When there are many studies in a given 
meta-analysis, the test has high power to detect a small amount of heterogeneity that may 
be clinically trivial (Higgins, Thompson et al. 2003). Thus, it is prudent for a distinguished 
meta-analyst to use equally heterogeneity assessment as weIl as qualitative evaluation of 
the combinability of the studies. 
Méta-Régression 
Correlations linking categorical altercating variables to ES, from time to time, 
provide us with potential associations that are especially useful to our understanding of a 
given question. In other words, a meta-regression graph or analysis helps in assessing the 
relationship between study results and study characteristics (Guzzo, Jackson et al. 1987). 
Therefore, meta-regression facilitates further formulation of potential causal inferences and 
strives for understanding of assorted results. Examination of moderating variables (e.g., in 
our case, type of antipsychotic used, dosage of medications, type of scale, etc.) via meta-
regression analysis adds to theory development and increases the richness of empirical 
work. 
However, Cochrane discourages usability of this method in meta-analysis involving 
less than 10 studies. 
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Présentation des résultats 
When the meta-analytic procedures are complete, it is important to present the 
information in the fashion that is easily accessible and easy to follow. This can be done 
through multiple venues. We must report the number of included and excluded studies. For 
the included studies, a brief report explaining the design, giving information on the number 
of subjects enrolled, the type of the setting, intervention, outcome measures, outcome, and 
demographic information can be granted. Later, for the excluded studies, descriptive 
information is desirable. In order to describe this section, one can include variables such as 
the state of the articles (e.g., ongoing studies, etc) (Higgins and Green 2005). A clear table 
separating the excluded from the included studies would be an asset. However, the number 
of studies retained from the searches can be presented in a fashion recommended by the 
Lancet, starting from searches of the search engines leading to exclusion and finally the 
number of studies retained for the purpose of meta-analysis (Moher, Cook, Eastwood, 
Olkin, Rennie and Stroup 1999) (refer to appendix section). 
Further, studies included in the meta-analysis with their associated effect estimate, 
sample size, p-value, and confidence level (usuaIly set at 95%) aside to a blobbogram are 
used to graphically show the impact of the overaIl effect. Depending on the software used 
and preference of the authors, the variances as weIl as the z-value are also reported. It is 
noteworthy that, the interpretation of the variance is the same as the CI. 
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"Blobbogram" 
The Blobbogram is a graphical representation of the studies included in the overall 
meta-analysis. It consists of horizontal lines, diamonds, black 'blob' and lozenge(s) 
associated with effect estimate that shows how weIl the treatment did compared to the 
control, for example. The blobbogram facilitates the interpretation of data, and compares 
studies side-by-side. Hitherto, its use is to detect bias in meta-analysis. One example of this 
kind of graph is what we have achieved in our meta-analysis, provided in the figure 1, 
where each horizontalline represents a different comparison (often time, individual trials). 
Other types of graphs are Radial Plot and/or Funnel plot, Galbraith Plot (Galbraith 
1988; Galbraith 1994), Abbe Plot (Song 1999), Thompson sensitivity Plot, Bayesian 
Shrinkage plot, and Cumulative plot (Lau, Antman, Jimenez-Silva, Kupelnick, Mosteller 
and Chalmers 1992). Examples of this graphical representation are provided in a study by 
Pai and colleagues (Pai, McCulloch et al. 2004). However, there exists other methods to 
represent the effect estimate, for instance one can refer to Stem and Leaf display, which has 
no graphical interface (Rosenthal 1995). For instance, the Forest plot shows the information 
from the individual studies at a glance (e.g., amount of variation between studies and an 
estimate of the overall result) (Lewis and Clarke 2001). 
In meta-analysis, we must note that graphs are also adapted in the interpretation 
of data and investigating heterogeneity (Baujat, Mahe, Pignon and Hill 2002). 
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Interprétation des résultats 
To interpret the findings, meta-analysts refer to the rule-of-thumb by Cohen. Cohen 
summarizes effect sizes of continuous data into 3 groups: 1) small if the effect is less than 
0.20; 2) medium if near 0.50; 3) and large if it is equal or bigger than 0.80. This 
categorization differs for the correlation coefficient or odd-ratio effect estimates. For the 
correlation coefficient, the effect size estimate is considered small if it is 0.10 or lower, 
medium if it is near 0.25, and large if it is equal or larger than 0.40. For odd-ratio, it is 
considered small if it is equal or less than 1.50; medium if it is around 2.50 and large if it is 
equal to or higher than 4.30. It is noteworthy that this arbitrary classification corresponds to 
the distribution of effects across meta-analyses amassed by Lipsey and Wilson (Lipsey and 
Wilson 1993). AIso, it is important to mention that this method of interpretation has its own 
limitation, for instance, it does not take into account the context of the intervention. For 
example, a small effect may be consequential if the intervention is for severe and a fairly 
intractable illness such as for cancer. Furthermore, the yielded omnibus effect estimate can 
be translated into a percentage in order to demonstrate the possible effect of the treatment 
or treatment strategy. For the conversion table of the effect estimates to percentage, a 
reference to the article by Freemantle and Geddes (Freemantle and Geddes 1998), or 
Zakzanis (Zakzanis 2001) can be made. 
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"Comprehensive Meta-Analysis" 
Comprehensive meta-analysis (CMA) software (http://www.meta-analysis.com/) 
was developed by a team of experts in meta-analysis both in United States and United 
Kingdome. During our study of meta-analytic approach on the add-on treatment of SSRI to 
antipsychotics in schizophrenia, we have been observant of advantages of CMA, for 
instance it includes a wide array of sophisticated options for data entry, analysis, display, 
structure, and data manipulation. 
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Résultats 
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Caractéristiques des études 
Five hundred ninety-one (591) possible articles emerged from our search. 552 
studies were rejected based on the evaluation of the abstract and 28 studies on the 
evaluation of the article, based on: 
(i) Type of studies (e.g. reviews, case studies, challenge studies, surveys, 
retrospective studies, open-label trials, post mortem studies, molecular studies, 
letter-to-the-editor, book chapter, and cross-over studies); 
(ii) Type of population (e.g. non-human subjects, patients with comorbid conditions, 
non-schizophrenia patients); 
(iii) Treatment type (e.g. non-SSRI antidepressants, non-pharmacological therapy); 
(iv) Complete unavailable data (Salokangas, Saarijarvi, Taiminen, Kallioniemi, Lehto, 
Niemi, Tuominen, Aho1a, and Syvalahti 1996; Poyurovsky, Pashinian, Gil-Ad, 
Maayan, Schneidman, Fuchs and Weizman 2002; Bustillo, Lauriello, Parker, 
Hammond, Rowland, Bogenschutz and Keith 2003). 
The remaining Il studies which responded to our inclusion criteria (data was 
available for each study) were clinically heterogeneous (Table 1), in terms of: (i) SSRI 
medication: fluoxetine (5 studies), fluvoxamine (2 studies), sertraline (2 studies), 
citalopram (1 study), and paroxetine (1 study); (ii) antipsychotic drug: atypical (3 
studies), typical (5 studies), not specified (1 study) and mixed (2 studies); (iii) 
psychiatric assessment: SANS (7 studies) and PANSS-N (4 studies) (Note: Studies 
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were classitied according to population description explicitly stated by authors); (iv) 
patient type: chronic (7 studies) and non-chronic (4 studies); (v) psychiatrie setting: 
inpatient (5 studies) and outpatient (6 studies); (vi) treatment duration: from 4 weeks to 
4 months; (vii) type of data: LOCF or ITT (4 studies) versus study completers (7 
studies). 
Two studies, tirst, Poyurovsky, et al (2002) and second, Bustillo and colleagues 
(2003) were not primarily designed to assess negative symptoms. Three studies were 
using previously published data; hence, they were ignored from analysis (Tai mine n, 
Syvalahti, Saarijarvi, Niemi, Lehto, Ahola and Salokangas 1997; Silver, Aharon and 
Kaplan 2003; Silver, Nassar, Aharon and Kaplan 2003) (refer to table 1). 
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Table 1. Study characteristics. 
SSRI-Dosage EPS/ TX-Studies • N SSRI Anti psyehotie Seales PT Depression Duration (mg/day) 
eontrolled (weeks) 
Silver & Nassar 30 Fluvoxamine 50-100 Un-speeified SANS Chronie / Yes/Yes 5 (1992) Inpatients 
Buchanan et al 33 Fluoxetine 20-80 Clozapine SANS Not- responder/ No/Yes 8 (1996) Outpatients 
Spina et al 30 Fluoxetine 20 Typieal SANS Chronie/ **/Yes 12 (1994) Inpatients 
Arango et al 32 Fluoxetine 20 Typieal SANS Outpatients Yes/Yes 8 (2000) 
Silver et al 52 Fluvoxamine 50-100 Typieal SANS Chronie/ Yes/Yes 6 (2000) Inpatients 
Lee et al (1998) 36 Sertraline 50 Typieal PANSS- Chronie/ Yes/Yes 8 N Inpatients 
Poyurovsky et al 24 Fluoxetine 20 Olanzapine SANS 1 st episode/ No/Yes 8 (2002) Inpatients 
Bustillo et al 20 Fluoxetine 20-60 Olanzapine PANSS- Outpatients Yes/Yes 16 (2003) N 
Salokangas et al 75 Citalopram 20-40 Typieal PANSS- Chronie/ **/No 12 (1996) N Outpatients 
Mulholland et al 20 Sertraline 50-100 Mixed SANS Chronie/ **/Yes 4 (2003) Outpatients 
Joekers et al 25 Paroxetine 20-30 Mixed PANSS- Chronie/ **/Yes 12 (2005) N Outpatients 
PT=patients; TX=treatment; In=Inpatients; **=no data . 
• References are marked with an asterisk (*) in the bibliographie section. 
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Synthèse quantitative des données 
Eleven randomized, double blind, placebo-controUed trials, with paraUel arm design 
(N= 393 patients at end-point) were identified in which add-on SSRI therapy was compared 
to antipsychotic monotherapy. Using end-point (end of trials) data, no significant 
differences were observed between the treatment groups for negative symptoms 
(standardized me an difference Hedges's g= 0.178; p= 0.191; random-effect model), yet it 
was slightly heterogeneous (Q= 16.83; p= 0.078). An overaU 5% attrition has been 
calculated (refer to Figure 1). Interestingly, for baseline data, a composite effect size 
estimate for negative symptoms was obtained, boarder on significance (N= 412; 
standardized mean difference = -0.179; p= 0.072), suggesting a potential study bias. No 
significant differences were detected at baseline between the SSRI and placebo groups for 
age, sex, positive, depressive and EPS, 
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Figure 1. SSRI add-on therapy for negative syrnptOtnS of schizophrenia 
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Controlling for the masked effects, secondary analyses were performed. 
Standardized mean differences for negative symptoms were ca1culated for the following 
categories: antipsychotic type (typical, atypical or mixed), SSRI medication (fluoxetine), 
psychiatrie setting (inloutpatient), psychiatrie assessment (P ANSS-N & SANS) and 
treatment duration (more or less than 12 weeks). It is noteworthy that Evins and Goff 
(1996) recommend a period of no less than 12 weeks for polypharmacy with add-on SSRI 
of negative symptoms. A non-significant composite standardized mean difference was 
reached for aIl of the secondary analyses performed. 
A run was also carried excluding Bustillo and colleagues (2003) and Poyurovsky et 
al (2002). A low and significant effect size for negative symptoms was reached (N= 339; 
Hedges's g= 0.277; CI= -0.087 to 0.640; p= 0.049) and homogeneous (Q= 12.312; p= 
0.138). Additionally, when studies were divided based on severity of illness (chronic 1 non-
chronic), a moderate effect size for negative symptoms was obtained for the chronic group 
of studies (N= 274; Hedges's g= 0.386; CI= -0.018 to 0.791; p= 0.014), and so the 
composite effect estimate was no longer heterogeneous (Q= 9.060; p= 0.170). When studies 
were separated into LOCF or ITT versus study completers, similar results were yielded. 
Effect estimates were non-significant and smaIl: LOCF or ITT [ES=0.093; P-value=0.594] 
and study completers [ES=0.240; P-value=0.225]. 
Sensitivity analysis has been performed in order to control for the methodological 
limitations (end-point heterogeneity & baseline differences in negative symptoms). This 
has been carried out based on the mean values reported by different researchers. Mean 
values were transformed into Z-scores using their standard deviations for assessing a 
pooled variance (refer to Table 2). The new data were then analyzed for differences 
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between the two study conditions (SSRI vs. PLC) and between initial scores and final 
appraisal with a 2x2 factorial ANOV A. The critical level of significance was set at 5%. 
Patients improved in time (F= 21.94, df =1, 40, p<O.OOl) but no differences observed 
between the two medication regimen (F = 2.64, df=l, 40, p=O.l12 ns). Same method was 
replicated for the so-called "chronic patients", again time-treatment interaction emerged to 
be non-significant (F:::: 0.88; df=l, 24; p=0.357). 
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Table 2. Z-scores obtained for each study. 
Baseline End-point 
Studies • Placebo Add-on SSRI Placebo Add-on SSRI 
ZI Z2 Z3 Z4 
Buchanan et al 
-0,2465 0,1661 -0,0991 0,1219 (1996) 
Spina et al (1994) 0,4650 0,5421 0,1908 -1,2916 
Arango et al (2000) -0,1817 0,0260 0,0519 0,1038 
Silver et al (2000) -0,0622 0,0895 0,1513 -0,1632 
Silver & Nassar 0,6276 1,0015 -0,4254 -1,2037 (1992) 
Poyurovsky et al 0,7726 0,8178 -1,1366 -0,8255 (2002) 
Mulholland et al 0,0880 -0,0176 0,0176 -0,0880 (2003) 
Salokangas et al 0,3939 0,4166 -0,3676 -0,5802 (1996) 
Lee et al (1998) -0,0246 -0,0082 0,0082 0,0246 
Bustillo et al (2003) -0,2367 0,3836 -0,3020 0,1551 
Jockers et al (2005) 0,3811 0,8675 -0,4104 -0,8302 
• References are marked with an asterisk (*) in the bibliographie section. 
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Discussion 
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The aim of our meta-analytic investigation was to question the effect of treatment 
with SSRI add-on therapy for burden of negative symptoms. Our meta-analysis provides no 
clear evidence for the polypharmacy with SSRI for negative symptoms of schizophrenia 
based on the following reasons. First, there is lack of statistical significance in the 
composite effect estimate at end-point, comparing SSRI add-on to antipsychotic 
monotherapy. AIso, this effect remains non-significant ev en when baseline data is 
compared with end-point. Second, the lack of efficacy is not attributable to clinical factors 
such as age, sex, and positive, depressive or extrapyramidal symptoms, or any of the 
potential confounding factors such as psychiatrie setting and assessment, type of 
antipsychotic, and specifie type of SSRI. Our result is in concord with the newly developed 
collaborative consensus statement on negative symptoms by National Institute of Mental 
Health and Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(NIMH-MATRICS) (Kirkpatrick, Fenton, Carpenter and Marder 2006). 
The challenges in pursuing this meta-analysis are discussed in the form of questions 
and answers. These questions and answers can be categorized as, methodological 
variability, neuropharmacological likelihood explanation, and clinical perspective. 
Furthermore, we have provided sorne possible explanations to the results that we have 
obtained. 
81 
Aspect méthodologique 
Questions which surfaced were the following: 
1- Why was the end-of study scores used instead of assessment of change? Why 
have we not considered using mean changes to calculate effect size estimates? 
Although we have considered this approach, this method was abandoned, 
because it would not have allowed identifying the potential study bias (in this 
case, barely significant) that we found when we compared baseline negative 
symptoms between the two groups (SSRI vs. placebo). 
2- Why were cross-over studies exc1uded from the meta-analysis? 
We preferred not to inc1ude these studies, mainly for two reasons. First, we kept 
the methodological homogeneity in our meta-analytic evaluation. Second, we 
also had other methodological reasons to mIe them out. There were three cross-
over studies: Vartiainen, et al. (Vartiainen, Tiihonen, Putkonen, Koponen, 
Virkkunen, Hakola and Lehto 1995); Brancato, et al. (Brancato, Barbini, 
Regazzetti, Colombo and Smeraldi 1994); and Friedman, et al. (Friedman, 
Ocampo, Elbaz, Parrella, White, Bowler, Davis and Harvey 2005). In the case of 
the Vartiainen, et al. 1995 study, BPRS was used for symptom evaluation. As 
for the Friedman, et al 2005 study, the study was not designed to primarily 
assess negative symptoms. Nonetheless, cross-over design has other problems, 
such as carry over (a type of period-by-intervention interaction), and the risk of 
drop-out due to longer duration compared to parallel group trials. In addition, 
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meta-analytic techniques, particularly of the statistical type, are limited wh en 
adding cross-over studies to parallel arm trials. 
Based on the low number of included studies (N=ll), this would litnit the power of 
detecting heterogeneity; however, there should have been very large differences between 
studies if it were detected. 
3- Why was the investigation ofheterogeneity not explained explicitly? 
-As recommended in the literature (Glasziou and Sanders 2002), in order to 
address the heterogeneity problem, we performed the following sub-analyses 
(masking effects), controlling for: 
(i) the type ofscale used (PANSS-N & SANS); 
(ii) psychiatrie setting (inloutpatients); 
(iii) duration oftreatment; 
(iv) SSRl medication (fluoxetine); 
(v) the type of antipsychotic (typical, atypical or mixed). 
AlI of the above mentioned sub-analyses provided non-significant effect estimates. 
Furthermore sub-analysis separating the studies by the state of the illness 'chronicity' 
showed that the effect size was no longer heterogeneous. The benefit of our meta-analysis 
is that aIl our analyses were calculated using random effect model. This model adjusts for 
heterogeneity among the effect size estimates, as it allows the study outcomes to vary in a 
normal distribution between studies. 
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AIso, since the majority of our studies inc1uded 20 to 75 subjects, we used Hedges' 
g as opposed to Cohen's d, which takes into account the variability in sample sizes. 
Another serious concern that one can bring to light has to do with the way we have 
accounted for attrition. It appears that only RCT completers were included in our analyses. 
Such a method can be seen as even more flawed than the somewhat undesirable Last 
Observation Carried Forward. Moreover, it can be said that the results of our analyses tend 
to be biased and have very limited generalizability; hence, we reason by the following 
position: this selection method noted in the data extraction of the manuscript was chosen to 
keep high number of patients (observed cases). Statistically, the use of LOCF or ITT by 
itself would lead to biased results and the true alpha may exceed the pre-given alpha. Yet, 
we have used both types of data (LOCF or ITT, and full data without attrition) in our 
analysis so to be c10ser to real-life situation. However, the sub-analysis of studies by 
separating them into LOCF or ITT and RCT completers groups has yielded similar results. 
Both effect-estimates were non-significant and small. 
4- What role did the length of the studies in affecting the results have? 
It is of our interest to note that 3 out of the 4 studies which pertained "chronic" 
patients - were observed to be, possibly the responding subgroup. This leads to 
the question of whether the important relevant 'chronicity' was of the patients' 
conditions or of the additive treatment employed. This would appear to be a 
significant caveat in the non-finding of a therapeutic effect to additive 
SSRI pharmacotherapy for negative symptoms in patients suffering from 
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schizophrenia. An attempt at separating the studies by "chronicity" was 
appealing. However, we did not follow this apptoach as it could have been 
misleading given the fact that the terminology regarding "chronic" group was 
not clear (Lesage and Morissette 2002). Also, by dividing the group considered 
as non-chronic based on study length, we would have had only 3 studies of short 
duration. These 3 studies comprise one study where negative symptoms were 
not the primary variables (weight gain was their primary variablef In addition, 
the non-chronic category pertained also to studies that were not explicitly 
asserting the state of the illness. 
Aspect clinique 
Two clinical questions arose. First, why was Obsessive Compulsive Disorder 
(OCD) one of the criteria of exclusion, even if the patient met aU the other inclusion 
criteria? InitiaUy, according to Berman and coUeagues (Berman, Chang and Klegon 1999), 
this subtype of schizophrenia patients have distinct pathophysiology, treatment response, 
and clinical course. For instance, these schizophrenia patients have a poorer prognosis. 
Subsequently, by excluding comorbid OCD, we have insured patient homogeneity. 
Second, why was there a discrepancy when the inclusion criterion shows 
"schizophrenia spectrum disorder" where the whole rest of the paper is written as if it is 
about schizophrenia? In response, aU of the studies included in this meta-analysis involved 
schizophrenia, with the exception of the Bustillo study (Bustillo, Lauriello, Parker, 
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Hammond, Rowland, Bogenschutz and Keith 2003), which involved both schizophrenia 
and schizoaffective patients. Then again, in this study, negative symptoms were not the 
primary variables of investigation. As a reminder, we carried out a sub-analysis by 
removing studies which were not designed to primarily assess negative symptoms. 
Aspect neuropharmacologique 
Our results are of relevance to the neuropharmacology of antipsychotic medications. 
One possible rationalization to our yielded effect estimate would be through the 
neurobiological alterations. According to both animal and human data, a dopaminergic 
hypoactivity in the medial prefrontal cortex (mPFC) seems to underscore the negative 
symptoms of schizophrenia (Grace 1993; Finlay 2001). In this vein, the efficacy of second-
generation antipsychotics in the treatment of negative symptoms has been atiributed to their 
ability to modulate prefrontal dopaminergic activity. In animaIs, second-generation 
antipsychotic drugs have been shown to increase dopamine release in the mPFC 
(Heidbreder, Foxton, Cilia, Hughes, Shah, Atkins, Hunter, Hagan and Jones 2001; 
Westerink, Kawahara, De Boer, Geels, De Vries, Wikstrom, Van Kalkeren, Van Vliet, 
Kruse and Long 2001; Ichikawa, Li, Dai and Meltzer 2002). Similarly, brain imaging 
studies have shown a (partial) prefrontal restoration in schizophrenia patients during 
treatment with second-generation antipsychotics (Honey, Bullmore, Soni, Varatheesan, 
Williams and Sharma 1999; Stip, Fahim, Mancini-Marie, Bentaleb, Mensour, Mendrek and 
Beauregard 2005). This prefrontal restoration could be related to the 5-HT2A1D2 ratio of 
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affinities of second-generation antipsychotics. With the exception of amisulpride (Meltzer, 
Li, Kaneda and Ichikawa 2003), second-generation antipsychotics have greater affinity for 
serotonin 5-HT2A receptors than the y do for D2-dopamine receptors, which is not the case 
for any first-generation antipsychotic drug (Meltzer, Matsubara and Lee 1989). In animaIs, 
serotonin and dopamine exert antagonist actions (Kostrzewa, Reader and Descarries 1998). 
By b10cking serotonin receptors, atypical antipsychotics would disinhibit dopaminergic 
neurons in the PFC (Kapur and Remington 1996). As such 5HT2A antagonists (e.g. 
ritanserin) have little effect on dopamine release in any brain region. However, when the y 
are combined with a selective D2/D3 antagonist (e.g. raclopride), 5-HT 2A antagonists 
facilitate dopamine release in the prefrontal cortex (Andersson, Nomikos, Marcus, Hertel, 
Mathe and Svensson 1995; Westerink, Kawahara et al. 2001). In this very context, some 
authors have noticed that the use of SSRI medication for negative symptoms appears 
somewhat paradoxical (Silver 2004). How could indirect serotonin receptor agonists such 
as SSRI relieve negative symptoms when serotonin receptor antagonists such as second-
generation antipsychotics are thought to do so? However, actually, from a 
psychopharmacological perspective, inhibiting the re-uptake of serotonin and blocking the 
5-HT2A receptors might not be a real paradox: 5-HT2A and 5HT2lA receptors are strongly 
associated with each other and the 5-HT 2A blockade could induce its anti-negative/anti-
depressive effects presumably by an indirect activation of 5-HT1A receptors. SSRIs inhibit 
the re-uptake of serotonin, leading to an increased serotonin level, which acts at 5-HT1A 
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receptors. I1's therefore a synergistic mode of action. Insofar as SSRI add-on therapy does 
not relieve negative symptoms, there might simply be no paradox. 
Yet again, SSRI medications are indirect agonists at 5-HTIA receptors, which also 
modulate dopaminergic transmission. 5-HT1A and 5-HT2A receptors have opposed 
neurochemical and behavioral effects (Marek, Carpenter, McDougle and Price 2003; 
Celada, Puig, Amargos-Bosch, Adell and Artigas 2004). For instance, 5-HT1A receptor 
agonists can stimulate the release of dopamine in the PFC (Ichikawa and Meltzer 1999). In 
the CUITent context, it can thus be argued that augmentation of antipsychotic therapy with 
SSRI (which are indirect 5-HT1A agonîsts) may increase dopamine release in the PFC, 
therefore pro vi ding an additional relief of negative symptoms. 
In short, by aggregating small numbers of available studies (N= Il), and considering 
the above mentioned question and answers, our meta-analysis showed no evidence of an 
effect for treating negative symptoms in schizophrenia. This would lead us to opt for other 
strategic methods such as, biopsychosocial approach, which is also recommended by the 
recent Canadian clinical practice guidelines (2005) for treatment of schizophrenia. 
With insignificant change in this symptoms during add-on therapy, the guideline 
recommends to re-evaluate diagnosis, to increase the dosage in cases of multiple-episode 
patients, and in case of lower side-effects, to maintain observation of these patients with 
uninterrupted combination therapy for longer than 8 months. Therefore, further clinical 
placebo controlled, randomized trials with higher enrolled number of patients with 
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concurrent consideration of the guideline is warranted. Additionally, with regards to 
categorization approach to diagnosis of schizophrenia, the literature emerging from our 
systematic review teaches us to find a precise and clear definition for classification, i.e., 
chronicity, and negative symptoms. Henceforth; we must incorporate this new terminology 
into our new trials. 
Nevertheless, the result of the current meta-analysis facilitates not only for the 
clinical scientist, but also for physician in order to minimize trial and error when co-
prescribing SSRI's for management of schizophrenia persisting negative symptoms. 
Although our result failed to provide heightened evidence for this combination therapy for 
multiple-episode schizophrenia patients, it may provide insight into pharmaco-genetic 
\ 
approach by helping to design safer and more efficient drugs. 
/ 
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. Conclusion 
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The mam purpose of this meta-analysis was to put ample evidence in simple 
comprehensi ve form, in order for clinician and researchers to integrate the new findings as 
part of there clinical examination and to use as a guideline. Thus our meta-analysis was 
produced out of necessity, to aggregate constructive information, from the cryptic data, 
abbreviated injoumals and other documents (printed or non-printed)(Glass 2000). 
With the experience of carrying out other meta-analysis (Thomton, Van Snellenberg 
et al. 2006), extensively investigating the literature on the method and the laws associated 
with this approach, and taking into account what has been accompli shed by the Cochrane 
group, this worl<. can be summarized as the following: 
Meta-analytic approach helps to address sorne of the challenges in psychiatric 
research. For instance, in the existence of multiple answers to a given question, which 
prevent us from solemnly relying on the significance tests of a few or solitary result as an 
appraisal of its worth. Also, it assists us in apprehending recurring outcomes with the 
matching trend. Thus meta-analysis consists of multiple studies, even in the presence of a 
non-significant result, which is more influential to the evidence than a single significant 
result or non-systematic reviews. This last notion is subjective. For instance, a study with 
presence of high number of subjects may precisely provide with ample power to reach a 
generalizable conclusion, such is the case with Schizophrenia Outpatient Health Outcomes 
(SOHO) study (Novicl<., Bousono, Suarez, Olivares, Montejo, Haro, Edgell and Ratcliffe 
2005). 
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In the completed meta-analysis, owing to the availability of data both for baseline 
and end-point of trials, we have performed a more robust statistical procedure to detect 
apparent sampling bias. An orthogonal 2 by 2 factorial analysis of variance was performed. 
In order to carry out this analysis, we have first transformed aIl the reported mean, standard 
deviations and n's per each arm of the study to a standardized Z score. Then the Z-scores 
were used in the ANOV A. This article is the first meta-analysis that has demonstrated the 
maITiage of significance test with effect size to investigate time treatment interaction effect; 
thus detecting sampling bias. 
In general, meta-analysis has certain caveats (Rosenthal and DiMatteo 2001). Meta-
analysis shares the same disadvantage as traditional, non-quantitative, narrative reviews of 
the literature. Its strength lies in, recognizing the background in a given domain; keeping 
the statistical significance in perspective; limiting wasted data; asking for more focused 
research questions; and finding moderating variables. In perspective, our meta-analytic 
~ 
investigation provides research-clinicians with knowledge on the appropriateness of CUITent 
practice-polypharmacy-for the treatment of negative symptoms in schizophrenia by 
understanding the best CUITent evidence, eleven randomized controlled trials. 
The above article is an example of meta-analysis performed on continuous data. It 
provides with answers to sorne of the clinical concems in clinical psychiatry with regards to 
decision making for better treatment planning in schizophrenia research and guidance for 
future search. In other words, this meta-analysis integrated medical professionals' expertise 
with aggregating evidence, consequently helping clinician to make sound conscientious, 
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explicit, and judicious decision pertaining to treatment regimen of patients suffering from 
negative symptoms in schizophrenia with SSRI co-administration. 
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of antidepressants has been thollght to be of rotelltial in-
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symptoms would eventually lead to a relief of secondary 
negative symptoms. ln clillical praclice. il ha, heen e~ti­
maied that antidcprcssants arc prescrihcd as adjunclivc 
lrcalment in approxirnalely olle Ihint of ~chizophrcnia 
patic.ntsY IhJwevcr. add-on thcrapy with antidepressants 
such as mOlloamine oxidase inhibitors (MAO[s)'" or tricy-
clics" in schizophrenia ha~ produced limited results_'6 
More rceently, seleclive seroLOnin rellptakc inhihitol's 
(SSRI:;) have been invcstigmed as augmentation I.hcrupics 
for thç negutivc symploms of sehizophrcnia. On the basis 
of prcliminary' results, SiI\'er~ hus proposed the usage of 
SSRI augmentation therapy for these enduring symptoms. 
However; olher stlldies pllblished so far have prodllced 
connicting resultsY'lS " Cochrane registerert syslemutic 
rcview by Whitchc:ld ct a1. I <' showcd that ad!l-on antidc-
pressant for pcrsons with schizophrcnia and comorbid de-
pression may be qftherapelltic value; yel. Whitehead et <lI. 
reviewed a sm<lll number of trials, which ma)' hm'e led to 
a pm,sible study bias. so the interpretation of their result 
should be donc Wilh cure. A new qllantiwlive review of 7 
trials (N "" 2(2) by Rummel'and eollcagucs.'" showcd tlmt 
combination of antipsychotics with lIntidcprcssants ma}' 
pèrhaps be effective in controlling predominant negative 
symptollls. However. they report onl}' 3 studies with SSRI 
(also included in our rneta-mlalysis). and so 10 draw a COI1-
dusion on SSRI add-on therapy w(Juld be lirnitcd. Never-
thcless. the authors :Issel'! that their tïntling needs to be 
substantillted by fUl1her larger-sized trials.:" 
Also it is noteworthy that Ùle number of pmticipants in 
these studies has been small. ranging ti·om.20 patients" to 
75 patients." These studics did Ilot include cnough pa-
tients to !Ictect a 20% differcnee bctwcen groups in symp-
tom improvcment. which is ·the clinical standard for thc 
phannaeoJogic studies in sehizophrenia." To deteet sllch a 
difference hetween groups, it is required that a trial in-
c1udc 131 pnrtiçipauts pel' ,;Iudy ann (n = .05; power. 
80%).~· 
To rcach the sample sizc rel]uircu for deteeting a 20% 
difference between groups (power. 80%). we conducted a 
meta-analysis of stlldies assessîng SSRI add-on therapy 
for the negative sympt.ollls of schizophrenia. This meta-
analysis raiscd the sam pic si/.c in eaeh Mudy arm to more 
than 131 p:micipants. The rcslIlts of this meta-analysis 
arc of therapcutic imponance. çonsîdering the ehl'Onic 
nature of negatîve symptoms. They (:lluld abo shed Iight 
on the potentinl role of serotonin in the pathophysiotogy 
of..negative s)'lIlptoms. 
J\'lETHOD 
Data Sources 
Systematic review of the lilerature on SSRI add-oll 
therapy for the negativc symptoms of schil.Ophrcnin \>"as 
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pcrformed. Keywords uscd for the seureh wcrc ,\'l'llb,-
phl'C'l1ia and (for SSRl) s('rlraliT/e, CÎlaloprilm. paroxC'-
fine . .f7uoxeline, and .fluvoxal/line. The seareh engines 
were PsyclNFO, PuhMed (MEDLlNE) (1967-2005), and 
Cllrrent.COllt.;nIS (1993-2005). Hand search or puhlished 
rcvic'" articles. as wcll as eross-rctcrencing, have becll 
earricd out to galher fllrthcr data. When relevant. aut.hol'S 
were contacted for mi,sing data. Phannaceutical compa-
nies were ntso contacred to re\rieve unpubtished data (no 
l'llrthcr records were round). 
Study Selection 
A consensus was reached umong authors on the,studies 
l'etained or disc:Jl'ded. on the basis of the following inclu-
sion and exclusion criteria. 
Inclusion Criteria 
Studics were relllined if (1) SSRI add-ol1 ther:.tpy wu~ 
compared with untipsychotic tre<ltment: (2) patients had 
a dingnosis of il schizophrenia-speclTulTl disorder: (3) 
the clinical trial was randornized, dOllble-hlind, placebo-
cOlltrollCd with parallcl-arrn design: und (4) negalivc 
symptoms w<!rc asscs~cd with the Scale for the Assess-
ment of Negative Symptoms (SANSf' or the Positive and 
Negative Syndrome Scale-negalive subscale <PANSS-
N):'';'" befme (haseline) and after follow-up (end point). 
Overall. these sentes have heen delllonsirated 10 have 
high intcm,lI ('onsistcnç)' and cxtcmul validit} for the 
populatiun group.:'! f'urthcr, th,'se .walcs have bccn rc .. 
poned to be rel:.ttivel}' comparable. 15.2h JI 
Exclusion Criteria 
Studies werc discardcd if (1) schiznphreniu patients 
had bccn diagJl(lsed with cOnlorbid obscssivc-eompulsivc 
disorder ('05M criteria); (2) the study assessed the· em-
cac)" of MAO!, uicycJic. dual-action, or atypical antide-
pressant, (e.g., hupropion); (3) the study had ineomplete 
or uml\'nilable data; or (4) a crossover study design was 
cll1ployed. 
Data Extraction 
and Quantitative Data Synthesls 
Two reviewel's (A.A.S. nnd S_P.) independently ex-
tracted data: disagrecll1el1ts werc rcsolved by consensus. 
lJsing Comprehcnsi,·c Meta-Amllysis.!J effect size csti-
mates were derived frol11 the differences in negutive 
symptoms between schizophrenia p,uients treated \Vith 
add-on SSRI (SSRI group) and patients on placebo (pla-
ceho group), both bc!'ore (haseline) and artel' trcaunent 
(cnd point). Erfeel sizc cstirnatcs wen:. ca1culutcd fwm 
samplc sizc, means, and st,lIldard deviations (PANSS-N 
score· or SANS total score) for each group of patients: 
SSRI :U1d placebo. When availahle. full data without at-
trition were preferred to intention-to-treat or last· 
observalion-carried-forward clata. Within a random-
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Table 1. Study Charactcristics of Randomizcd, lloublc-Hlind, l'Iacebo-Conlrollcd Trials of SSRI Add-On Therapy for the 
Negative Sympwms'of Sèhizophrenia 
SSRI Dosago f,I'SIJ).p,es~i(m Trt!alrnel1l 
StUtly N" SSllI (m~/d) Amip.ychmk St.de P"lll{'fll DCSÇliptioll COJHn,Ued f)uration, wk 
SH"er and N~tSs.1r:!.! )0 J "luvoxumÎne 50-100 Um:pcdfic'(1 SMiS L:hl'\)nicl1npntil~nt y,.,/y,., 5 
Rllch~nnfl el nl21 33 Pluoxellne 21}-80 Clô/.ilpine SA!I<S Nont'e~pùnd~r/OII{palit"ni ""IYe; ~ 
Spimù.>1 i111~ . 30 Fluox\.'lin(· 20 Typic"l SANS Ch10nkllnpulknl 100 "/'/(.s 12 
Ar.mgo C't a\~·~ 
·31 1'\uoxc1inc :on Typical Si\NS OUlpntkm yçsJ'r'cs H 
Sil\'ef el al:;.(, 52 Hu\"o"311Iine ~(HO() Typical SANS Chronil:.lltll);)IÎonl Yt;'':)/"lt,''s 6 
l..ce 1:"1 al li 36 ScrtraJinc ~O Typknl f'ANSS-X Chnmi clIn pml"nt Yt's/Yt'~ 8 
l'oyul'ov~kf ct. nl Ct' 24 Ffuoxctinc 20 Ol(inlnpint.' SA:\S J:\I cp.;<iodcflnpaticl1l N,l/Y". R 
Buc;tHIt> er'n!lt- 20 Huoxctinc- ~()--<)I) OhmznpÎnc l'ANSS-N ()l1tpnlk'nt Vl:f;/Yt."~ Hi 
Salo'k.m,g,as el ~e:)t, 15 Cilalopnml 20-10 TypklJ! PANSS-N ClllvniclOufpUlifl1l "/Nc) 12 
MlIlhoHnnd et al4tJ 20 Scrlralinc 50" 100 Mi""ù SANS C'hnmk/Outp •• ticnt '%«/Yt~ft 4 
Jockcl'sDSchcnthl er arll 25 Paroxotlnc 20 .... )0 \1ixC'd P;\NSS-N ( ·hront~lOutpati\~n. l'S*jye:. 12 
"'NumlX!f (If p;'lIi~mt.'i: who complcrcd rh,' tritlL 
.... D:Ha t'or UlÎ!:-i l'Uwtkular ~md)' \\'\)1'(" jlmvid('d by tht'< Ul.nh\.)T. 
Ahhrt,,'iatinils.: EPS :::: eXlrnpyranlich,1 symplOlT1s, Pt\NSS~N :::. Pn.:;itt\'c ~lIld Ncg!lIÎ\'c Syndrome Scnh>n"wuive suhscnlc. S/\NS S<.'ii.lc fol' the 
I\~<;.(':.;~rnt'nro" N~':g.:ui\'e Symplonls, SSRl!!! ~ele-clivè St'rOlollÎn rt'lIplake ïnhihhor. 
4<1t< 'l:: 11U di'Ha. 
effc~ct$ model, cffect size eslinwtc$ were dcrived u~ing 
Hcdgcs' g;'" which providcs cffcct Si'l.CS :1djustcd .for 
sampk size. Random-cffects nlockls, bcing lIIore strin-
gent th an fixed-effects model~, allow population-lèvel 
i nferc necs.:;4 
ln oJ:(ler 10 control for ba"c1inc clinic:ll charactcristics, 
effeet size eslimates were performed with available data 
(sec Table l). For lige (7 studies). positive symproms (10 
sludics). ücprcs;;i"c symploms (9 sludics), and c:mapyr,,-
rnidal syll1pl(}rn~ (6 studic~), erreCl cSlimalcs were caku-
luted on Ihe' basis of mean scores and SDs for both com-
paril;on groups. Tn the cuse of sex (9 studies), the effeci 
si7.e estimalc \Vas cornpuled liS a nonpararnctric "mlc dif-
ference," Ilsing l11ale/fèmale ratios. In addifion, ènd poilu 
c!;lla were used to calculate effeet size estÎmates for pos-
itive. deprl'ssive. ,tm\ cXlr:lpyralllidal symptoms. POl' 
sorne studics. ûXlmpyramidal syrnptoHl wlal ,cores \Vere 
not available, ollly extrapyramidal symplOtll subscale 
scores. These subseores were collapsed using D-STAT·2 
ln gener:llc a toml extmpyramidal symptom scorc (Illean 
differences). 
Homogeneit)' of Effect Size Estlmàt~s 
Tt is more legilimatc 10 ag!,'Tcgale clTeel size cslimlllcs 
when effecl sizes'are homogeneous_ A univc:rsal mean 10 
indlc:lIe Ihe exlem of helerogeneily (variability due 10 
chance, due 10 sCllk lIsed, etc.) is the applielllion of ~tatis­
liml test, rrequcruly portra}cd as Cochriln X' lest llr the 
Q lest/statistie. The Q stmislÎc is simil,lr to X2 statislics 
but uses met,l-annlytic datu to examine the homogencity 
orthe cffect si l,CS includçJ in Ihe studiès:::' TIl US, wc h;\Vc 
cll1culated the Q stalislÎc for Ihe cff CCI size eSljrnatc~ of 
the slUdies inc1uded in the meta-analysis (baselint>, and 
cnd point. separately). Significancc was dc.fincd a priori 
il~ p < ,1./\ signifîcanl rcsult is an iildicalion of the pres-
ence ()f moderating variables with;n Lhe datasel. 
Rt;SUI.:rs 
Study Characterlstics 
l'ive hundred ninety-one possible articles emerged. Of 
tnese, 552 studiel' were discardcd on the basis of the 
cvalu:lfion of the nhSlract and 28 slUtlics 011 the basis of 
Ihe evaluation of the article, according 10 the following 
l'casons: (1) type of mticle/study (e.g .. review. case sludy. 
clmllcngc study, :mrvey. l"ctmspcclivc ~Iudy. opell-\;lb,,1 
trial, p()slmorlclll study, llloiceular study, Ietter LV the 
edita!': book chaptèr. and crossover sludy), (2) type of 
population (e.g., 1l0nhuman subjects. plltÎcnts with comor-
bid condilion,. nonschi7.ophreni:l patienls), (3) trelltrncnr 
ty~ (e.g., lIon-SSRI nntidèpressanis_ nonphal1l1!lcologii:: 
ther:lPY), und (4) incomplete or unavuilable daln ..... •• The 
rellulÎninl1 11 studjc~ rcspondcd to our inclusion critl'ria 
(data werc llvnil:lb!c fOl" cm:h sludy). 
The Il sludies included in fhe meta-analysis were 
clinically hNerogeneou& Cnlble 1), in the following 
arcas: 
• SSRI medication: fluoxetÎne (5 sl\Idies), fluvox-
amine (2 studies). serlraline (2 studies). cllaloprnm 
(1 sludy), and p"roxctine (I sludy); 
• antipsychotic drug: mypical (3 studies). typicnl (5 
studiesl. !lot specified (1 smdy). :md mixed (2 
stutlles): 
• p~ychialric asscssrllCl1t: SANS (7 ~ttldics) and 
PANSS-N (4 studies): 
• pulient type (Note: Sludies were dassified lIccord-
ing 10 population description <!xplicitly stlltcd by 
author;;): chronic (7 ;,Welles) ilnd nonchronic (4 
sludies); 
• psychiutric setting: inpaticnt (5 studies) ,md outpu-
tient (6 swdies); 
• [reatlllenl duration: l'rom 4 weeks 10" m()mhs; 
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t'il!ure 1. Errect Sizes of Randomized 1)'i"lsof SSRI Add-On Therapy for Jliegalive Symploms of Schizophrenia 
EHoct FQ'Jors Favors 
Follow-Up eila1ion Name SSAI Placebo SSRI Total Na EIt""1 p Value 
Aller 8oslillo 01 nr38 PAN$S Fluo)(olioo ._-~ 30 -.4.,3 .223 
Altor Poyurovsky Cl nl37 SANS FluQtotin(] ~4 -~"2 .~14 
Aller I:lLlch~Mn el Itl21 SANS ï-Iuotetinc 33 -.214 .534 
AIIO( ArJ.rlg() cl al 3S SANS Fluou:::tln(J 32 '·~.O$3 .880 
Aller Leo olnl 1? PANSS Sertralino 36 -016 .961 
Aller Mulholland et aJ~O SANS Ser1ralina 26 .'03 .788 
Alter $.ulOkan(JQ' Cl tlrJ9 PANSS Gr1oJoprOlT'! 75 .204 .376 
Sifwer ct at'36 AtteT SANS FluYol:tlmino 52 .280 .:)14 
Alter JOckefs-Scherubt el al'" PANSS Parm:otine 2.5 .349 .380 
A'ter Silver and Na. .. sar-"2 SANS FllnloxsmÎne 30 .864 .022 
Altor SfJinaot (11'8 SANS' FhloOxotin(] 30 1.278 ,001 
Random" Aftor(11) --,+- 393 ,178 .191 
BG'loro Ilustillo (JI 0138 PI\NSS FluQx(lt1no 30. -606 ,099 
B~IOt'o jock€ln;-SrJlf>Tubi et al" 1 PANSS Parcuc\lnll 25 -.586 .147 
8oforo BvctllUlUn 01 nl21 SANS FbJOxoUno --+-- 33 -.405 .2'" 
Belote Sil\>m a.na Nossn,zz SANS F-luvoxamine 30 -328' .360 
Belore At'ango cl (1:135 SA.'\IS Aooxetine 32 -.'95 .57~ 
8010ro Silvcr et o,t36 SANS Flu,,'oxllminn -----r----- 53 '70 .537 
90foro Stllnn el el' (I SANS FluotetinCl 30 -088 ,806 
Belore f'oyurovs.ky el ru3? SANS FIUOtetino :JO -051 .886 
aeJo((). Sa.l,\<.~nou~ ct :.\t39 
Lee e:1 al 17 
"I\NSS (' ..d3k\jlll\1"1\ 87 -oro .Q1'3 
Oeloro PANSS SElrtralml;' 36 -.016 .962 
Belore Mulholland el al40 S""S Serlfaline 26 .101 .792 
Randomb Beloro(11) 412 -.179 .072 
-2.00 -1.00 1.00 2,00 
Eltect SilO, SD 
;lNs in thjs figure pt~I1ain b<Hh li) laSl-obsl."rvulion-~nri'i(·d-forNmcl (LOCF) and in[~nlion-IO-rreat (rrl) data. as is Ihl.!' ~asc for Hwnillo e.11l1. (LOCF) 
and Mulholland 01 al. (1'1-0. 
hAnnJysis based oflcramh)DI-cffects m()(leL. 
AbbrcviaIÎon!\: P/\NSS ': Positive :md ~q;'lti\'c Syndrome ScOtI". S'\l"\S;:::, Scak t'ol the A.sscs\m(,'llt uf Ncg,ativc SYIlIf'lOlIlS, SSRI::;. !\(,~1C'(,1i\'c, 
Sl'll)Woin rt'upwke inhihiwr . 
• type of dma: I:ISI-obscrvalion-cnrricd-forward or 
inlcn\Îon-to-trCtl! (4 s!udics) vcrsu~ study COHl-
pieters (7 studics). 
lt is noteworthy that 2 studies wcre not primarily 
designed to assess negative symptoms:,,·JH Studies 
reporting previollsly lIsed data werc- withdrawn l'rom 
analysi~,,7 .... I" 
Quantitative Data Synthesis 
A total of Il randomizcd, dOllble-blind, placebo-
controlled trials, \Vith pamllel-arm design (N = 393 PlI-
tients at end point) werc identificd in whieh add-on SSRI 
thempy was.compared with antipsycholic monothcrapy. 
No signiticant differences were found between the tr<!at-
ment groups for negative symptollls using end point data 
(adjllsred. Hedges'g '" 0.1711: p= .191; random-effecls 
Jl1odel) (Nole: An overall 5% aurition has hecn ('[lleu-
lated_) (Figure 1). Intcrestingly, for basclinc data. a com-
posite etTcet SIZC estimate for negntive symptoJ1ls \Vas 
obtaincd tlult bordered on signifie'lnce (N = 412: adjustcd 
Hedges' g '" -0.179; p = .(72), suggesting 11 potential 
.tudy bias. For age. sex, and positive. depressive, and 
extrapyramidal symptoills. no signitïcant differenccs 
between the SSRI and plJcebo groups were detected at 
baseline. 
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ln ()rder 10 eontml for masked cffccts. seeondary 
lInalyscs were perfonllcd. Effee! siz\! estilllat\!~ -for· neg-
ative symptoms were c;i1culated according to the follow-
ing categories: antipsychotic Iype (Iypical. alypicaJ, or 
mixed). SSRJ mcdicatiotl (fluoxetine Ys_ others), psychi-
atrie setling (inpatient/ontpatienr). psychiatrie assessment 
(PANSS-N and SANS). and trcarment duratioll (Iess lhall 
12 wcekf. or longer lh31l or elJnal to 12 weeks) (Note: III 
add-on SSRI for IreatmCt1l of negative symptoms, a 
long-term !luJ'ution of trcarment or no less than 12 weeks 
is rccomlTlellllcdl~). Thcsc sccond:lTy analyses ail pro-
vided nonsignilîcant composite cffect size estima!.es for 
ncgative symptoms. A run was also pClformed excluding 
the stlldies by Bustillo and colleagues3' and POyllrovsky 
et aL" A low and significant elTeet size estimate for nega-
tive s)'mptoll1s wa.~ re:lched (N = 339; adjllsted Hedges' 
g = 0.277; 95% Cl = .. ·O.OK7 to 0.640: p = .04'), ln addi-
tion, whcn stlldics were dividcd according 1.0 severity of 
i\llles~ (chronie/nonchronie). a mo(\crate effcet SilC for 
negatil'c symptoms was obluincd for the ehronic group 
of studics (N = 274: adjusted Hcdgcs' g = 0.3B6: 95% 
CI = -0.018 to 0.791; P = .(14). Additionally. when stud-
ies were separated into last-observution-carried-forward 
or intention-to-tre:!t versus study cOl11pleters. similar re-
sults were yielded_ Both effect estimates w<!fe non-
signilieant and. small: last-obscrvntion-earricd-forward or 
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'fable 2. Z Scores Oblained for Each SI udy 
Buchanan cl !l1':1 
Sj1ina\'i a11t. 
Ar.:m~o cl nI":' 
Silvcrct ul}{' 
S 11 \'~r and N"Msnr'!l 
p(\yurx)\'~k\' Cf al:\1 
Mulh011,ml el al'" 
IMokollgns <1111"" 
U'" ct al" 
Bustîllo el "11~ 
.Iockers·Schc .. ubl ~t al" 
lla~clinc 
·fU~65 
0.4650 
-0.1817 
··1).0612 
0.6176 
0.772(1 
(I.OSSO 
O.39.W 
..{l.0246 
~).2:><,7 
(1,3811 
Alld.()n 
SSRI 
(l.JMl 
o.~·m 
O.()1fiO 
0JIllQ~ 
1.()()15 
Il.RI7R 
.. 0.0176 
0.4166 
··O.O(l8~ 
t1.38J6 
O,R675 
End PoilU 
-n.{)~QI 
O.190~ 
OIJ.~I~ 
O.I.~IJ 
-().4~$4 
.. 1.116(, 
(J.OI7b 
··(U676 
O.(l()82 
.. (U010 
.. OAI04 
Md·O" 
SSRI 
().121~ 
-1.2916 
0.10:18 
.. O.16J~ 
-1.20}7 
-<IX!55 
.. (J.OSSo 
.. ·n.5802 
(W24Ô' 
0.1551 
~1.83112 
intcntion·\o·treat teffect size::: O,f193; p value", .594) and 
slUdy completers (effeet size = 0.240; p value = .225). 
The sel of Il studies (end point datll) included in Ihe 
mettl-lmalysis \Vas slightly helerogeneous (Q = 16.830; 
P .078). 111ey wde no longer hClcfügeneous when the 
\\!udic~ WCI'C div ided .nccording to ~evcrity of iIIness 
(so culled "chronie patients") (Q '" 9.060; P = .170). Aiso. 
wh Cil the 2 studies not designcd to primarily assess 
negative symptom~ were exduded, effect size estÎnmtes 
or negativ·.,: symptoms were no longer hcterogencous 
(Q= 12.312; p=.J3H). 
Sensitivity Analysis 
To control for Ihe mcthodological shortnllnings 
uforcmentioncd (end point hctcrogcncity und basc!inc 
differellces in.negntivc symptoms). l1lean values reported 
by different rese:lfchers 'vere tr<\llsfonned imo z scores 
using their s.tandard deviations for assessing a pooled 
variance ('l'able 2). The new data llttained \Vere then ana· 
Iyzed for differences between tbe 2 stlldy conditions 
(SSRI vs. placebo) and belween initial scores IUld final 
appraisal wilh a 2 x 2 faetorinl analysis of vuriuncc. Thc 
crÎtieul levcl of significllllce wa~ set at 5%. Patients illl-
proved in lime (F '" 21.94. dl' '" l ,4{); p < .(JO 1) but no 
differcnces wcrc \)bscrved bctwecn ~thc 2 Il1cdic~tion 
regimens (P=2.64. df lAO; p=.112 NS). The same 
method wus' replieated for the so-çalled "chronic pu· 
tienls," and again time-treatment inter:Jction emerged ro 
benol1significunt (F O.RS: df,. 1.24; P = .357). 
DISCUSSION 
The objec!Ï ve of this IlICl.a-analysis wa& to t1eltTlIline if 
SSRI add·nfl thcrapy provides relief of ncgalivc s)'mp-
10l11S among schizophrcnia patients. Using search en· 
gilles. Il r~lIldomi7.ed. double-nlind. placebo-controJJed 
trials were identitïed, involving 393 patients. Using Com-
prehensive Meta-Analysis.)1 effeci !>i7.c e;;lÎmales for dif-
ferences in negulivc symplollls (end point data) between 
SSRT for Nt~llati"e Symptoms of Schi7.0phrenia 
bOlh groups (SSR! and placebo) wcrc clliculmed. Within 
il rartdOlll-effects model. .1 nonsigni riCllllt composite effccl 
size estimaic wu;; ontained. suggesting thal SSRI uug-
mentlltion thcrapy does Ilot rclievc Ihe neg.ative symptoms 
of schizophrenia. Secondary analyses were perfor01cd 
10 control l'or potellliai cllnfounding f.\CtoTS. such 'L<; 
psychiatrie settillg (Ïnpmieni/ollipalient). psychiatrie ,L~' 
sessment (PANSS·N/SANS). :mtips)!chotic type (typkall 
atypicalJmixed), speciFie SSRI (Iluoxeline vs. others). and 
tœutment duration (shortcr Ihan 12 weeks or longer th an 
or equal to 12 wccks). Again. no significant differcnces 
c!llergcd bctwccn rh..: SSRI !lnd the pl:Jcebo groups on 
negati\'c symptom~. However. n significant but low effect 
size cstÏlmlle for negati\'c 'symptoll1s W/L, obtllined whcn 
the 2 studics not prÎll'mrily designcd 10 assess changes in 
ncgalive s)'mploms (BustÎllo et aL~ tmd Puyurovsky el 
al."') wcre excluded. ln addition, a 1110demte and signifi· 
cam dfect size for neglltive symptoOls was rcached u;;Îl1g 
end point data whcn 11 run was perfonncd with siudics 
involving chmnk patients. or intercsl. the~e palient;; <Ire 
thc most likcly to henctit l'mm SSRI add-Oll Ihemp)! sincc 
negalÎve ~ymptoms <tre <uuong Ihe most endurillg $igns 
of the disordcr.' Nevc.rthcless, after tl factori.d nnalysis 
ll~ing baseline and end point dala, even the so·called 
"ehronie" schizophrenia patient did not seem 10 profit from 
thi> treatment !'egimen. Mort!()ver, it must he taken into 
considemlio!l thut no operational definition of "chrol1ie 
schizophrcnill"-a sligmali/.ing terrn-has bccn çonsensu-
an y cstaiJIl\hcd. ". 
This IIrsl set of analyses comprised 2 limilalÎons. First, 
a trend towmd signiticance was obscrvcd when th..: corn· 
posite cffee! sizc .cstimate was culculated for differences 
in buseline negative symploms. Patients in the' placebo 
group tended 10 have fewer negativc sy!11ptom~ lit baseline. 
suggesling a potenti~1 study bias. In addition, .:nd point 
efrect ~ize eSIÎm'ltes for ncgative symptoms appcarcd to 
he heterogeneolls. However, in the current meta.-analysh. 
the helerogeneity problelll must not he ovcrestimllted, for 
2 l'casons: (1) the numhcr of studic$ included was sll1111l 
\ Il), which limits the power of the Q stulÎslÎc/' and (2) 
for Onr seconda!'y analyses (e.g .• severity of illnes,), cffect 
size estimales for ncgative symptoms were no longer 
hClcrogencolls. 
1'0 comrol for Ihese sho!1colll i ngs. menn, and SOs 
on PANSS-N and SANS scores were Iransformed into 
l scores (SSRI and place.bo groups: basdine and end point 
data), nllowing for the calculatinn of u composite 2 x 2 
factorial tltlnlysis of variance of negative symptoms, with 
SI'OUp und time as inderen(\cnr variables. A Ilo!lsignificant 
rcsult wus oblained. l'urthcr suggcsting that SSRI aug-
mentation thempy docs Ilot relieve Ihe negative "yl11ptoms 
of schiz.ophrenill. 
The results of Ihe currcnt meu-analysis provide 110 cleur 
evidence for the presumed efiicacy of SSRI augmentation 
treatment of negative symptoms. Whereas previotiS studies 
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relied on samples too small 10 detect c1inically signifïcant 
differences, pooling of the published randomized, double-
blind, placebo-controlled sludies that wcre methodologi-
cally homogcneous provided a sampJe of more than 150 
patients per arm; however, the global sample size for the 
11 studies rcntained small (393 patients). Tn addition, the 
study provides evidence tha! this lack of efficacy can 
not be attributed to clinical differcnces in age, sex, posi-
tive symptoms, deprcssive symptoms, or extrapyramidal 
symptoms. However it is imperative to touch hase with 
clinical and methodological issues in this debate. For dis-
cussion of clinical implications and methodological con-
cerns related to primaTy and secondary negative symp-
toms, please refcr to the studies by Moller" and Rummel 
and colleagues?O 
In conclusion, our findings offer no support for poly-
pharmac)'--{:ombining antipsychotics and SSRI-at Icasl 
not for the treatment of negative symptoms of schizophre-
nia for which there was a pOOl' rcsponse to anlipsychotics 
aJone. 
DrUK names: bupropion (W("\\bulrin and 01hef:;), citalopram (CC!cX3 
and olhrrs). clozapine (Clozaril. Fa7~1Clo. and oLhers). OUi1xetine 
tProz3c and others), olan7apine (Zyprcxa), paroxcline (Paxil. Pexeva, 
"nd olhers). scr\nllinc (Zolofn. 
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Résumé de l'article (en français) 
Parmi les signes qui font partie de la définition clinique de la schizophrénie, figurent 
les symptômes négatifs. Ces symptômes négatifs (le retrait social, l'émoussement des 
affects, l'avolition, etc.) sont des signes qui sont difficiles à traiter. Même avec l'arrivée des 
antipsychotiques atypiques, les symptômes négatifs demeurent la plupart du temps 
réfractaires au traitement. Alors, une hypothèse a été proposée, l'examen de l'effet de la 
potentialisation des médicaments antipsychotiques par les ISRS pour traiter les symptômes 
négatifs. Les résultats d'essais contrôlés, de quelque manière prometteuse, ont produit des 
résultats contradictoires. Objectifs: Pour surmonter cette anomalie dans les résultats, nous 
avons examiné l'effet de la potentialisation des médicaments antipsychotiques par les ISRS 
pour traiter les symptômes négatifs en utilisant une approche de revue de littérature 
quantitative. Méthode: Une recherche a été exécutée en utilisant les moteurs de recherche 
automatisés, le PsychINFO, le PubMed (MedIine), et le CUITent Contents. La recherche 
manuelle des articles de type de synthèse aussi bien que par vérification des références 
d'article publié ont été effectuées. Des compagnies pharmaceutiques ont été également 
contactées. Des études ont été maintenues si : (i) La poly-pharmacie avec ISRS a été 
comparée au monotherapy antipsychotique avec des patients schizophrène ; (H) l'essai 
clinique formé de façon randomisée, à double aveugle, et parallèlement contrôlé par la voie 
de placebo; (Hi) des symptômes négatifs ont été évalués avec le « SANS» ou avec le sous 
échelle de « P ANSS » pour les symptômes négatif. Avec un consensus, AAS et SP ont 
extrait et vérifié les données indépendamment basées sur des critères d'exclusion et 
XVIII 
d'inclusion prédéterminée. Des évaluations de la taille de l'effet ont été calculées en 
utilisant le logiciel « Comprehensive Meta-Analysis ». Résultats: Onze études ont répondu 
à nos critères d'inclusion. Avec un modèle d'effet d'aléatoire « random effect model », une 
taille de l'effet non-significative (sur la fin des études) pour des symptômes négatifs a été 
obtenue (N= 393; Hedges' g= 0.178; p= 0.191). Cependant, quand des études ont été 
divisées selon la sévérité de la maladie, une taille de l'effet modérée et significative a 
émergé pour les études faisant participer des patients prétendus 'chroniques' (N= 274; 
Hedges' g= 0.386; p= 0.014). Conclusion: La méta-analyse que nous avons effectuée 
montre un effet négligeable pour amélioration des symptômes négatifs en pol y-thérapie 
avec ISRS dans la schizophrénie. 
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L'Échelle D'appréciation des Symptômes Négatifs (SANS) : 
SANS scale takend from Lecrubier and Boyer (Lecrubier and Boyer 1987; Lecrubier 1997). 
ÉCHELLE D'APPRÉCIATION DES SYMPTÔMES 
, NÉGATIFS [DÉFICITAIRES} 
(SC ALE FOR THE AsSEssMENT OF NEGATIVE SYMPTOMsj 
SANS 
N.e. ANDREASEN 
FEUILLE RESUMÊE DE COTATION' 
Trnduction française :'y' LECRUBIER et P. BOYER 
NOM 1 1 Il! 1 1 1 1 1 1 1 1 1 PRËNOM 1 1 1 1 1 Il! 1 1 1 1 
SEXE U AGE UJ DATE UJUJW 
EXAMINATEUR 1 1 1 1 Il! 1 1 1 1 1 1 1 1 
Reponer l'intensité, selon le ,système général suivant: 
o -abseme • aucun(e) • inexistant. 
l - doute (sur une diminution) - discutable. 
2 - léger(e) 
.RETRAIT OU PAUVRETÉ AFFECTIVE 
1 - hllression figée du visage o 
[e:.:pression facial~ apparalt rigide. figée, mêcanique. On 
note une absence, ou une diminution, des changemenLS 
d'expression en rapport avec le contenu du discours. 
2 - Diminution des mouvements Spontanés C 
Le patient est assis, immobile durant l'entretien, et pré-
sente peu, ou 'pas, de mouvements spontanés. II l}e_ 
change' pas de posilion, ne bouge pas ses membres ... 
3 - Pauvrete de l'expression gestuelle 
Le malade n'utilise pas les mouvements de son corps 
pour aider à l'expression de ses idées, tels que gestes des 
mains, posture penchée en avant... 
4 - Pauvreté du contact visuel 0 
Le malade évite de regarder, l'autre ou d'utiliser ses yeux 
pOUr se:-:prirner. Son ~gard semble perdu, :lans le vide, 
même lorsqu~il parle. 
S - Absence de réponses affectives 0 
Ne rit ou ne sourit pas lorsqu'il y est incité. 
6 - Affect inapproprié 0 
1.: affect c,,-primé es! inapproprié ou incongru et non sim-
plement p~uvre et émoussé. 
3 - moyenne(e). 
t - imponam(e). 
5 - sévère. grave. 
7 • Monotonie de la voL" 0 
Lorsqu'il parle, le malade ne présente pas les modula-
tions vocales nonnales. Le discours est monotone, 
S . tvaluation globale de la :pauvreté affective 0 
[évaluation globale prend en compte la gravité de 
l'ensemble de l'êmoussemem affectif. Une importance 
particulière doit être donnée au noyau représenté par 
l'absence de réactivité, une diminution globale du vécu 
émotionnel, et son caractère inappropri{ 
sous-score: somme 1 à 7 00 
ALOGIE 
9 • Pauvreté du discours o 
C'est la reduction de la quantité de propos spontanés, 
aboutissant à des réponses brèves, concrètes et non éla-
borées aux questions. 
10 - Pauvreté du contenu du discours (idéique) 0 
Blen que les réponses soient suffisamment longues pour 
que le discours soit normal en quantité, il compone peu 
d'informations, le langage tend â elre vague, souvent 
trop abstrait' ou concret, répétitif, stéréotypé. 
11 • Barrages L.l 
1 c mabd., dhm spnn1.lntmcrH, <lU fi p~fIlr d'tu", qu,',,,. 
tl(ln, une im~rrupli\'n du C()Uf~ de S~ pensee 
1'2 • ;\llgm"matIQII d. la, I"w,,,"~ d"" rel'0nl'es 
La durt.e qUI S',ZCi)U!~ ~V.\Il! qu,> I~ lnalxk lie rèp,mde 
aux c,uesrion.<; .,.sl ,,1I,s ;ongu.! qt!t· !lnmlal"l'I1ellL li l'CUI 
sem nier "aillculC,", Il 11 ::i'pClldum cumpn' h, q\l!:stkm 
l :; • lËvaluarÎon gIQt",l~ 
L(:~ slgut,'f{ fHldcaires 4.1( l':doj;.ÎC ét..'lnt hl pauvtttt: ùu di;;~ 
,,)Urs cl t'die Ùl' ,;;m <t>meIHI. l'tv,.!u<lchm !!,1"b,,1ç ,l,ni 
l"Utlt'ulwl'\?mL'nt C'l lernr cumplc, 
""Il,,·SWfC: somme 9 à II 
AVOLITION • APATIUE 
1 4 • Toilt'ltl:' . h)'gîéne [J 
Vl:It'T1-f~nt~ lh~ghgt">;; .'lU 5~'!~S, d,CV't!11X ~r;lis.$e:lIx> i.Î(]eltr 
corp"fdk, 
15 • !\tanqu(' d'"""lJuht' :m ,,,,,,,ail Illl :1 /'".nl. 
L,t" In.al.a\-h~ à cl",,') Jt'f11,:~Jt:(;~ :1 H\)tl'.; .. ~r l,Hl ~~nrU~"f un ~l'npilH, 
l'lU une lBSènlùn $t.'oh'nn: en lve ...... !>l'Hl A~ . • f l.~nt:\-
(uer ;.;$ travaux rnl,";lg~rs, <:$1 h(lsp'lali"';, il 11<; par. 
(Idp,; pas d~ l~çon d'":lhl" nUl( ncti"jt~S du SCIVI"!", 
LJ 
nnetli~ ~"l phY"'I'''-; k sut,:! l'cm t'eSler dé~ hcures 
ùSSIS ~ur UUf;' Ch;li$f!, ;:111$ enm"pr~ndl\' spontanç!1le,\! 
tUl.e ~çti\-'ü~" 
17 • l~valmllion gl"halc D 
Un pÜld;; Hnp{Jrt~nll r<':I.U ~Hl\:1; al~('()rtIi1' :::1 un ütl d~~ux 
<)'lUp\ùme!. prcdOI11H'U1!lt; dans 1't':\',llu;\llim gk,ha'" s'Ih 
,(ltH l'aniculk,rcmem h'pp:lIHS, 
ANlffiDONIE • RETRAIT SOCL<\1. 
18 . lnt~dl5 ct aClivil4!:s de Inisirs [] 
LI," ,n;lbd~, plèscnté P<"1l ,Ile êCrl1n;S d'mlt;:~!5, f't?1l d anl-
vIlès ou de 'h,;ôhk,' L't,·"hHlIicl1 cl";1 prendn: l:n 
(omplt; ks ;1,SpCtOlS '1"alit:ml$ ct '1ual\llra,i!s üe n:s 
\n\érHs 
19 • lnlCréts ct ,1(:1 ivih~S st,:\'Ucls 
l,,:; ra~bdc, pl:llVI,m Ilrtx!llfer un.: <ÎunltlUIlOtl d,', lBI>?-
r';l" ri açBVHés ",xnd, ou ùu plaisÎT t:or",sptmclam 
20 • lm,apaclte fi vivre: lies rt'IIIUuns. ':Irolles 
ou illlÎlnes [J 
Le mlll:lIk rétif pn!$<:!Hcr """ int1lpaCII~ à d"vdupPCT 
de~ lelllliolt" étroites t>u intlmcs, ,'11 pal1llul!er 3\'l'C % 
famiDe (lU dl>, s\ljel$ du $CliC npPf>SC 
XXII 
21 • Relations ~""c l~" amis ri CQlIègut'$ 
b' II1"41t:k pt'LI ;lv,nt pl'U, nu pa~ d':U11IS el [an, ll<!iI 
d'tlrorts pour y l'eI11Nher. dl0islss;l11I d'Cm' pmtiquemt"rn 
tf~U~ ie t("nlp~ ~~ut 
22 - ÉVlllu"liml lllolm'" dt: 1'.U1hêdoni<: c,t 
du Telt'llit ~clal 
t:é\'alurlliù'1 glohale d'}!1 f(!l1th\~ ({'"IP!': dt la """l'rté de 
l'enscnlbl... synptomalique <lnhèdonie-fClrait s,l('BI en 
tenan! C<1I11I"<" dcs !1<'ml<::$ attCt1CI'I:" '1do" l'âge, le $i!K" 
li: SlatUI bnlllLti 
ATTENTION 
23 • Inallcnlinn dan.." les aCli"ilés sill::illle5 D 
Au t:OuT:\ de ses ~(IiVll~S. ÜU reblions $odales. le n',a1ade 
[JMait in:memif, Il (,c!flnle "perdu" 
::u. - lnaU<:lIIinn dur'UlI la ('"talion CJ 
PO\II' l'cv;!l,,,,, on Il''<I! dCI\1~ndcr d'~pdN le Inn! 
~'MONnE': ~t ;-',"(1\,,<,., .'~\~ prupr)~:"i'r d'tJ~ t~.preuvt'~ .;trhh· 
m0liq1..f,t.~$ ~trnph."!:- h~n,tJH ~:nmp((~ du nIVi'_IU ;:i-t"olmre 
Score Ct 0 .:rœUf. :S.;~)r~ 1 ~ 0 t'f<~Ur. maJ~ ili ... nt." h(-Sllt, 
Score 2. (~rr,,:ur. 5t:t.)l'è 3 1 .crrcl.tr$, 
Score 4, = :\ "m~un;, X()!'C ? e t:11I~ de J cm~Ul'$, 
25 • t, .. "lUtllilln ~l ... h.l,· n 
I.:èv:tlt.mion ;?,:"h;;l .. des l'0'5ihililr;, d'aUellliol1 ùu de 
,oncenlr.lIlOll, d,,!t tenir (()mpl~ d,,,, él~menls dîdqu<.><; 
el ,.k~ pcrlt)l1l1an~,,;; :!lIX IC~I" 
.;cure total (snmlnt- d.> IflU~ 1 .. , ilcms) DO 
~"mme tic!< ~'l11uallons, glohales LJO 
